<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes - Motuhifonua, SK - 2023 | Cochrane Library</title> <meta content="Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes - Motuhifonua, SK - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011507.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes - Motuhifonua, SK - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011507.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011507.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes" name="citation_title"/> <meta content="Soana K Motuhifonua&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Luling Lin&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Jane Alsweiler" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Tineke J Crawford" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Caroline A Crowther" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="c.crowther@auckland.ac.nz" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD011507.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/02/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011507.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011507.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011507.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Diabetes Mellitus, Type 2 [prevention &amp; control]; *Diabetes, Gestational [prevention &amp; control, therapy]; Dietary Supplements; *Hypertension, Pregnancy-Induced; Inositol [therapeutic use]; *Insulin Resistance; Perinatal Death; Premature Birth" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011507.pub3&amp;doi=10.1002/14651858.CD011507.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011507\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011507\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ko","pt","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","id","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011507.pub3",title:"Antenatal dietary supplementation with myo\\u2010inositol for preventing gestational diabetes",firstPublishedDate:"Feb 15, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011507.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011507.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011507.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011507.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011507.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011507.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011507.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011507.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011507.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011507.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8073 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011507.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/appendices#CD011507-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/supinfo/CD011507StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/supinfo/CD011507StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#CD011507-cr-0004">Soana K Motuhifonua</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#CD011507-cr-0005">Luling Lin</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#CD011507-cr-0006">Jane Alsweiler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#CD011507-cr-0007">Tineke J Crawford</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information#CD011507-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Caroline A Crowther</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information/en#CD011507-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 February 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011507.pub3">https://doi.org/10.1002/14651858.CD011507.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011507-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011507-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011507-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011507-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011507-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011507-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011507-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD011507-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011507-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011507-abs-0001" lang="en"> <section id="CD011507-sec-0001"> <h3 class="title" id="CD011507-sec-0001">Background</h3> <p>Gestational diabetes with onset or first recognition during pregnancy is an increasing problem worldwide. Myo‐inositol, an isomer of inositol, is a naturally occurring sugar commonly found in cereals, corn, legumes and meat. Myo‐inositol is one of the intracellular mediators of the insulin signal and correlates with insulin sensitivity in type 2 diabetes. The potential beneficial effect of improving insulin sensitivity suggests that myo‐inositol may be useful for women in preventing gestational diabetes. This is an update of a review first published in 2015. </p> </section> <section id="CD011507-sec-0002"> <h3 class="title" id="CD011507-sec-0002">Objectives</h3> <p>To assess if antenatal dietary supplementation with myo‐inositol is safe and effective, for the mother and fetus, in preventing gestational diabetes. </p> </section> <section id="CD011507-sec-0003"> <h3 class="title" id="CD011507-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth's Trials Register, <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, <a href="https://trialsearch.who.int/" target="_blank">WHO ICTRP</a> (17 March 2022) and the reference lists of retrieved studies. </p> </section> <section id="CD011507-sec-0004"> <h3 class="title" id="CD011507-sec-0004">Selection criteria</h3> <p>We included published and unpublished randomised controlled trials (RCTs) including cluster‐RCTs and conference abstracts, assessing the effects of myo‐inositol for the prevention of gestational diabetes in pregnant women. We included studies that compared any dose of myo‐inositol, alone or in a combination preparation, with no treatment, placebo or another intervention. Quasi‐randomised and cross‐over trials were not eligible. We excluded women with pre‐existing type 1 or type 2 diabetes. </p> </section> <section id="CD011507-sec-0005"> <h3 class="title" id="CD011507-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion, assessed risk of bias and extracted the data. We checked the data for accuracy. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD011507-sec-0006"> <h3 class="title" id="CD011507-sec-0006">Main results</h3> <p>We included seven RCTs (one conducted in Ireland, six conducted in Italy) reporting on 1319 women who were 10 weeks to 24 weeks pregnant at the start of the studies. The studies had relatively small sample sizes and the overall risk of bias was low. </p> <p>For the primary maternal outcomes, meta‐analysis showed that myo‐inositol may reduce the incidence of gestational diabetes (risk ratio (RR) 0.53, 95% confidence interval (CI) 0.31 to 0.90; 6 studies, 1140 women) and hypertensive disorders of pregnancy (RR 0.34, 95% CI 0.19 to 0.61; 5 studies, 1052 women). However, the certainty of the evidence was low to very low. For the primary neonatal outcomes, only one study measured the risk of a large‐for‐gestational‐age infant and found myo‐inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low‐certainty evidence). None of the included studies reported on the other primary neonatal outcomes (perinatal mortality, mortality or morbidity composite). </p> <p>For the secondary maternal outcomes, we are unclear about the effect of myo‐inositol on weight gain during pregnancy (mean difference (MD) ‐0.25 kilogram (kg), 95% CI ‐1.26 to 0.75 kg; 4 studies, 831 women) and perineal trauma (RR 4.0, 95% CI 0.45 to 35.25; 1 study, 234 women) because the evidence was assessed as being very low‐certainty. Further, myo‐inositol may result in little to no difference in caesarean section (RR 0.91, 95% CI 0.77 to 1.07; 4 studies, 829 women; low‐certainty evidence). None of the included studies reported on the other secondary maternal outcomes (postnatal depression and the development of subsequent type 2 diabetes mellitus). For the secondary neonatal outcomes, meta‐analysis showed no neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 4 studies; 671 infants; very low‐certainty evidence). However, myo‐inositol may be associated with a reduction in the incidence of preterm birth (RR 0.35, 95% CI 0.17 to 0.70; 4 studies; 829 infants). There were insufficient data for a number of maternal and neonatal secondary outcomes, and no data were reported for any of the long‐term childhood or adulthood outcomes, or for health service utilisation outcomes. </p> </section> <section id="CD011507-sec-0007"> <h3 class="title" id="CD011507-sec-0007">Authors' conclusions</h3> <p>Evidence from seven studies shows that antenatal dietary supplementation with myo‐inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth. Limited data suggest that supplementation with myo‐inositol may not reduce the risk of a large‐for‐gestational‐age infant.  </p> <p>The current evidence is based on small studies that were not powered to detect differences in outcomes such as perinatal mortality and serious infant morbidity. Six of the included studies were conducted in Italy and one in Ireland, which raises concerns about the lack of generalisability to other settings. There is evidence of inconsistency among doses of myo‐inositol, the timing of administration and study population. As a result, we downgraded the certainty of the evidence for many outcomes to low or very low certainty. </p> <p>Further studies for this promising antenatal intervention for preventing gestational diabetes are encouraged and should include pregnant women of different ethnicities and varying risk factors. Myo‐inositol at different doses, frequency and timing of administration, should be compared with placebo, diet and exercise, and pharmacological interventions. Long‐term follow‐up should be considered and outcomes should include potential harms, including adverse effects.   </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011507-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011507-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011507-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011507-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011507-abs-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011507-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011507-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD011507-abs-0022">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011507-abs-0019">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011507-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011507-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011507-abs-0023">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011507-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD011507-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011507-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011507-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011507-abs-0002" lang="en"> <h3>Taking myo‐inositol as a dietary supplement during pregnancy to prevent the development of gestational diabetes </h3> <p><b>Key messages</b> </p> <p>Women who develop gestational diabetes have a higher risk of experiencing complications during pregnancy and birth, as well as developing diabetes later on in life. The babies of mothers who have gestational diabetes can be larger than they should be and might be injured at birth. These babies are at risk of diabetes, even as young children or young adults. The number of women being diagnosed with gestational diabetes is increasing around the world, so finding simple and cost‐effective ways to prevent women from developing this condition is important. </p> <p>Myo‐inositol is a naturally‐occurring sugar found in cereals, corn, green vegetables, and meat, that has a role in the body's sensitivity to insulin. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if myo‐inositol is an effective antenatal dietary supplement for preventing gestational diabetes in pregnant women. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared myo‐inositol (given alone or in combination with another treatment) with no treatment or another treatment. We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found seven studies on 1319 women who were 10 weeks to 24 weeks pregnant.</p> <p><b>Main results</b> </p> <p>We are unclear whether supplementation with myo‐inositol is associated with a reduction in the rate of gestational diabetes. However, myo‐inositol may be associated with a reduction of hypertensive disorders of pregnancy. We are unclear whether myo‐inositol supplementation decreases the number of babies who were born large for gestational age.   </p> <p>The studies did not provide any information about the number of babies that died (either before birth or shortly afterwards), depression, or subsequent type 2 diabetes after delivery. There were no maternal adverse effects of therapy in the five studies that reported on this outcome; the other two studies did not mention this. </p> <p>We are unclear about the effect of supplementation with myo‐inositol on weight gain during pregnancy or on a baby with low blood glucose levels. This review did not find any impact on other outcomes, such as the risk of having a caesarean section or a large baby. This may be due to the studies being too small to detect differences in these outcomes and the outcomes not being reported by all studies. However, myo‐inositol may be associated with a reduction in the rate of preterm birth compared with the control group. </p> <p>The included studies did not report on many other relevant mother and baby outcomes, nor did they have any data relating to longer‐term outcomes for the mother or infant, or the cost to the health services. </p> <p>There is not enough evidence to support that giving myo‐inositol as a dietary supplement during pregnancy, prevents gestational diabetes. However, myo‐inositol may prevent hypertensive (high blood pressure) disorders of pregnancy and preterm birth. Further large, well‐designed, randomised controlled trials are required to assess the effectiveness of myo‐inositol in preventing gestational diabetes and improving other health outcomes for mothers and their babies. </p> <p><b>What are the limitations of this evidence?</b> </p> <p>We have little confidence in the evidence because there were not enough studies to be certain about the results and many of our review outcomes were not reported in the studies that we identified. The studies were also limited to populations from high‐income settings and so results may not be applicable to other populations. The studies also had some limitations on how they reported the methods.  </p> <p><b>How up to date is this evidence?</b> </p> <p>This evidence is up‐to‐date to December 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011507-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011507-sec-0130"></div> <h3 class="title" id="CD011507-sec-0131">Implications for practice</h3> <section id="CD011507-sec-0131"> <p>Antenatal supplementation with myo‐inositol for the prevention of gestational diabetes is a comparatively new  treatment. Whilst the results of this review show that myo‐inositol has promise in preventing the onset of gestational diabetes, there is currently insufficient evidence to support its routine adoption. The results of future research into the use of antenatal supplementation with myo‐inositol for the prevention of gestational diabetes will provide more robust evidence for informing and guiding practice. </p> </section> <h3 class="title" id="CD011507-sec-0132">Implications for research</h3> <section id="CD011507-sec-0132"> <p>The current evidence indicates that the effect of antenatal supplementation with myo‐inositol in reducing the incidence of gestational diabetes is unclear but may result in a reduction of the incidence of hypertensive disorders of pregnancy. However, higher‐certainty evidence is needed to confirm or refute this finding. The effect on other important infant outcomes is unclear. Further well‐designed randomised controlled trials are required and should be sufficiently powered to detect differences in relevant maternal and infant outcomes. They should include participants of varying ethnicities, with various risk factors for gestational diabetes such as obesity, polycystic ovarian syndrome, family history, and previous gestational diabetes; explore the optimal dose, frequency, and timing of supplementation; and report long‐term maternal, infant, and childhood outcomes. It is important that trials report on potential harms, including any adverse effects. In view of the availability of myo‐inositol as a dietary supplement and its relatively low cost compared with traditional interventions for preventing gestational diabetes, future RCTs should include economic analysis, or at least report on health service use and costs. If the efficacy of antenatal supplementation with myo‐inositol compared with placebo is established, then it will also be useful to conduct trials that compare the use of myo‐inositol with other preventative interventions, such as lifestyle (diet and exercise) or pharmacological interventions, such as metformin. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011507-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011507-sec-0008"></div> <div class="table" id="CD011507-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Myo‐inositol for preventing gestational diabetes: maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antenatal supplementation with myo‐inositol for preventing gestational diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: pregnant women (women with pre‐existing type 1 or type 2 diabetes are NOT included) </b> <br/><b>Intervention: myo‐inositol</b> </p> <p><b>Setting: hospital</b> <br/><b>Comparison: folic acid or placebo</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with myo‐inositol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gestational diabetes mellitus</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.53<br/>(0.31 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1140<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>GDM diagnosed using IADPSG 2010 criteria</p> <p> </p> <p>Random‐effects model</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1,000</p> <p>(67 to 196)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain during pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weight gain during pregnancy in the intervention group was 0.25 kg lower (1.26 kg fewer to 0.76 kg more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>831<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Random‐effects model</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hypertensive disorders of pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/>(0.19 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1052<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝ <b>Low</b><sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects model</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000<br/>(16 to 53) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean section</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.77 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>829<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>391 per 1,000<br/>(331 to 460) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perineal trauma</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.00<br/>(0.45 to 35.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1,000 </p> <p>(4 to 301)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Postnatal depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Development of subsequent type 2 diabetes mellitus</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded (‐1) for serious limitations in study design: due to unclear risk of selection bias in two of the six included studies; five of the six included studies were at high risk of performance bias; two of the six included studies were at high risk of detection bias; one study was at high risk of attrition bias.  </p> <p>b. Downgraded (‐1) for serious inconsistency; considerable heterogeneity, possible due to different study populations.  </p> <p>c. Downgraded (‐1) for serious indirectness; only one of the included studies was conducted outside Italy, and the Italian studies only included white women, the generalisability of findings is limited.  </p> <p>d. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias; one study was at high risk of detection bias.  </p> <p>e. Downgraded (‐1) for serious imprecision; evidence of imprecision with wide confidence intervals crossing the line of no effect.  </p> <p>f. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias; two studies were at high risk of detection bias.  </p> <p>g. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias. One study was at high risk of detection bias, and insufficient evidence to judge detection bias and subsequent judgement of unclear risk of bias. Due to insufficient evidence to judge allocation concealment in two studies and subsequent judgement of unclear risk of bias. Due to insufficient evidence to judge attrition bias in two studies and subsequent judgement of unclear risk of bias.  </p> <p>h. Downgraded (‐1) for serious limitations in study design: the study was at high risk of performance bias and detection bias for lack of blinding.  </p> <p>i. Downgraded (‐1) for serious Indirectness: only one study conducted in Ireland reported this outcome.  </p> <p>j. Downgraded (‐1) for serious imprecision: wide confidence intervals with very low event rates.  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011507-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Myo‐inositol for preventing gestational diabetes: infant, child and adult outcomes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antenatal supplementation with myo‐inositol for preventing gestational diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: infants of pregnant women</b> </p> <p><b>Setting: hospital</b> <br/><b>Intervention: myo‐inositol</b> <br/><b>Comparison: folic acid or placebo</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with myo‐inositol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Large‐for‐gestational age</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.65 to 3.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> <p>(56 to 258)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal mortality (stillbirth and neonatal mortality)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Composite of serious neonatal outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.07<br/>(0.90 to 10.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>671<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(8 to 91) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adiposity</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diabetes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurosensory disability</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded (‐1) for serious limitations in study design: the study was at high risk of performance bias and detection bias for lack of blinding.  </p> <p>b. Downgraded (‐1) for serious indirectness: only one study conducted in Ireland reported this outcome.  </p> <p>c. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias; one study was at high risk of detection bias.  </p> <p>d. Downgraded (‐1) for serious indirectness: only one of the included studies was conducted outside Italy, and the Italian studies only included Caucasian women. Thus, the generalisability of findings is limited.  </p> <p>e. Downgraded (‐1) for serious imprecision: evidence of imprecision with wide confidence intervals crossing the line of no effect.  </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011507-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011507-sec-0009"></div> <section id="CD011507-sec-0010"> <h3 class="title" id="CD011507-sec-0010">Description of the condition</h3> <p>Gestational diabetes is defined as any degree of glucose intolerance with onset or first recognition during pregnancy (<a href="./references#CD011507-bbs2-0020" title="AlbertiK , ZimmetP . Definition, diagnosis and classification of diabetes mellitus. Part 1: Diagnosis and classification of diabetes mellitus: World Health Organization Report. Diabetic Medicine1998;15(7):539-53.">Alberti 1998</a>). Gestational diabetes can lead to complications for affected women and their babies, making it crucial that effective strategies for its prevention are found. </p> <p>Screening for, and diagnosis of gestational diabetes, is usually undertaken between 24 and 28 weeks' of pregnancy. However, screening regimes vary from country to country, with some countries selectively screening based on risk factors (<a href="./references#CD011507-bbs2-0043" title="National Institute for Health and Clinical Excellence. Diabetes in Pregnancy: Management of Diabetes and its Complications from Pre-conception to the Postnatal Period. NICE guidelines [NG3]. London (UK): NICE, 2015.">NICE 2015</a>), and other countries using universal screening of all pregnant women (<a href="./references#CD011507-bbs2-0041" title="NankervisA , ConnJ . Gestational diabetes mellitus-negotiating the confusion. Australian Family Physician2013;42(8):528-31.">Nankervis 2013</a>). If thresholds for the oral glucose challenge test (OGCT) are exceeded, a diagnostic oral glucose tolerance test (OGTT) is used to confirm diagnosis, or a diagnostic OGTT can be used without screening by OGCT (<a href="./references#CD011507-bbs2-0040" title="MInistry of Health. Screening, diagnosis and management of gestational diabetes in New Zealand: a clinical practice guideline. Wellington: Ministry of Health, 2014.">MoH 2014</a>). </p> <p>A number of risk factors are associated with developing gestational diabetes (<a href="./references#CD011507-bbs2-0041" title="NankervisA , ConnJ . Gestational diabetes mellitus-negotiating the confusion. Australian Family Physician2013;42(8):528-31.">Nankervis 2013</a>): </p> <p> <ul id="CD011507-list-0001"> <li> <p>previous gestational diabetes;</p> </li> <li> <p>previously elevated blood glucose level;</p> </li> <li> <p>ethnicity: south and southeast Asian, Aboriginal, Pacific Islander, Māori, Middle Eastern, African; </p> </li> <li> <p>age 40 years or over;</p> </li> <li> <p>family history of diabetes mellitus (first‐degree relative with diabetes mellitus or a sister with gestational diabetes); </p> </li> <li> <p>obesity, especially body mass index (BMI) greater than 35 kg/m<sup>2</sup>; </p> </li> <li> <p>previous macrosomia (baby with birthweight greater than 4500 g or greater than 90th percentile); </p> </li> <li> <p>polycystic ovarian syndrome;</p> </li> <li> <p>medications: corticosteroids, antipsychotics;</p> </li> <li> <p>pregnancy weight gain.</p> </li> </ul> </p> <p>Some studies have reported an increasing prevalence of gestational diabetes (<a href="./references#CD011507-bbs2-0030" title="FerraraA . Increasing prevalence of gestational diabetes mellitus. Diabetes Care2007;30 (Suppl 2):S141-6.">Ferrara 2007</a>; <a href="./references#CD011507-bbs2-0060" title="ZhuY , ZhangC . Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Current Diabetes Reports2016;16(1):7. [DOI: 10.1007/s11892-015-0699-x]">Zhu 2016</a>). As many as 50% of women with gestational diabetes will develop type 2 diabetes within five years of the index pregnancy (<a href="./references#CD011507-bbs2-0038" title="KimC , NewtonKM , KnoppRH . Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care2002;25:1862-8.">Kim 2002</a>; <a href="./references#CD011507-bbs2-0057" title="VounzoulakiE , KhuntiK , AbnerSC , TanBK , DaviesMJ , GilliesCL . Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ2020;369:m1361. [DOI: 10.1136/bmj.m1361.]">Vounzoulaki 2020</a>). Gestational diabetes increases the risk of serious injury at birth, the likelihood of caesarean delivery, and the incidence of newborn intensive care unit (NICU) admission (<a href="./references#CD011507-bbs2-0021" title="AliS , DornhorstA . Diabetes in pregnancy: health risks and management. Postgraduate Medical Journal2011;87(1028):417-27.">Ali 2011</a>). Infants of women with gestational diabetes are at increased risk of developing obesity, impaired glucose tolerance, and diabetes as children or young adults (<a href="./references#CD011507-bbs2-0023" title="BoneyCM , VermaA , TuckerR , VohrBR . Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics2005;115:e290–6.">Boney 2005</a>; <a href="./references#CD011507-bbs2-0047" title="PettittDJ , BairdHR , AleckKA , BennettPH , KnowlerWC . Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. New England Journal of Medicine1983;308:242-5.">Pettitt 1983</a>; <a href="./references#CD011507-bbs2-0048" title="PettittDJ , AleckKA , BairdHR , CarraherMJ , BennettPH , KnowlerWC . Congenital susceptibility to NIDDM: role of intrauterine environment. Diabetes1988;37:622-8.">Pettitt 1988</a>; <a href="./references#CD011507-bbs2-0051" title="SilvermanBL , RizzoTA , ChoNH , MetzgerBE . Long-term effects of the intrauterine environment: The Northwestern University Diabetes in Pregnancy Center. Diabetes Care1998;21 (Suppl 2):B142-B149.">Silverman 1998</a>).<br/>  </p> </section> <section id="CD011507-sec-0011"> <h3 class="title" id="CD011507-sec-0011">Description of the intervention</h3> <p>Both non‐pharmacological and pharmacological interventions have been used to try to prevent gestational diabetes </p> <p>Metformin, an oral anti‐diabetic drug in the biguanide class, is the first‐line drug of choice for the treatment of type 2 diabetes (<a href="./references#CD011507-bbs2-0041" title="NankervisA , ConnJ . Gestational diabetes mellitus-negotiating the confusion. Australian Family Physician2013;42(8):528-31.">Nankervis 2013</a>). Metformin has been used to prevent gestational diabetes in pregnant women with a history of polycystic ovary syndrome (PCOS) with contrasting results (<a href="./references#CD011507-bbs2-0032" title="GlueckCJ , PranikoffJ , AregawiD , WangP . Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovarian syndrome. Fertility and Sterility2008;89:625-34.">Glueck 2008</a>; <a href="./references#CD011507-bbs2-0053" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD003053. [DOI: 10.1002/14651858.CD003053.pub5]">Tang 2012</a>). A randomised trial on the effect of metformin on obese pregnant women found that while fasting glucose and insulin were lower at 28 weeks' gestation in the metformin group, there was no difference in the risk of developing gestational diabetes, by either International Association of Diabetes and Pregnancy Study Groups (IADPSG) or World Health Organization (WHO) criteria, between those women who received metformin and those who received placebo (<a href="./references#CD011507-bbs2-0026" title="ChiswickC , ReynoldsR , DenisonF , DrakeA , ForbesS , NewbyD , et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinology2015;3(10):778-86. [DOI: 10.1016/S2213-8587(15)00219-3]">Chiswick 2015</a>). </p> <p>Myo‐inositol, an isomer of inositol, is commonly found in cereals, legumes and nuts (<a href="./references#CD011507-bbs2-0027" title="CrozeML , SoulageCO . Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie2013;95(10):1811-27.">Croze 2013</a>). It is a nutrient the body requires for cell membrane formation and cellular reactions to environmental messages (<a href="./references#CD011507-bbs2-0027" title="CrozeML , SoulageCO . Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie2013;95(10):1811-27.">Croze 2013</a>). Myo‐inositol is one of the intracellular mediators of the insulin signal and is correlated with insulin sensitivity in type 2 diabetes (<a href="./references#CD011507-bbs2-0037" title="KenningtonAS , HillCR , CraigJ , BogardusC , RazI , OrtmeyerHK , et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. New England Journal of Medicine1990;323:373-8.">Kennington 1990</a>; <a href="./references#CD011507-bbs2-0052" title="SuzukiS , KawasakiH , SatohY . Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type 2 diabetes. Diabetes Care1994;17:1465-8.">Suzuki 1994</a>). Due to its role as a second messenger, myo‐inositol has many benefits. When used as a co‐treatment in people with subclinical hypothyroidism and autoimmune thyroiditis, myo‐inositol aided maintenance of euthyroidism (normal production of thyroid hormone; <a href="./references#CD011507-bbs2-0044" title="NordioM , PajalichR . Combined treatment with myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis. Journal of Thyroid Research2013;2013:424163. [DOI: 10.1155/2013/424163]">Nordio 2013</a>). Myo‐inositol has been associated with an improvement in a range of conditions. These include: premenstrual dysphoric disorder (PMDD), a mood disorder disrupting the social or occupational life, or both, of affected women (<a href="./references#CD011507-bbs2-0025" title="CarlomagnoG , UnferV , BuffoS , D'AmbrosioF . Myo-inositol in the treatment of premenstrual dysphoric disorder. Human Psychopharmacology: Clinical and Experimental2011;26(7):526-30.">Carlomagno 2011</a>); symptoms of PCOS, a medical condition characterised by insulin resistance (<a href="./references#CD011507-bbs2-0046" title="PapaleoE , UnferV , BaillargeonJP , De SantisL , FusiF , BriganteC , et al. Myoinositol in patients with polycystic ovarian syndrome: a novel method for ovulation induction. Gynecological Endocrinology2007;23:700-3.">Papaleo 2007</a>); insulin sensitivity and ovulatory function in young women affected by PCOS (<a href="./references#CD011507-bbs2-0031" title="GenazzaniAD , LanzoniC , RicchieriF , JasonniVM . Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovarian syndrome. Gynecological Endocrinology2008;24:139-44.">Genazzani 2008</a>; <a href="./references#CD011507-bbs2-0042" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340:1314-20.">Nestler 1999</a>); hyperandrogenism in women with PCOS (<a href="./references#CD011507-bbs2-0039" title="MinozziM , D'AndreaG , UnferV . Treatment of hirsutism with myo-inositol: a prospective clinical study. Reproductive Biomedicine Online2008;17(4):579-82.">Minozzi 2008</a>); and increased number and quality of oocytes in women undergoing in vitro fertilisation (IVF) treatment for a previous history of infertility (<a href="./references#CD011507-bbs2-0055" title="UnferV , RaffoneE , RizzoP , BuffoS . Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecological Endocrinology2011;27:857-61.">Unfer 2011</a>).   </p> <p>Antenatal supplementation with myo‐inositol for the prevention of gestational diabetes is novel, and whether myo‐inositol is viewed as a nutritional supplement or as a medicine requiring prescription, seems to vary in different parts of the world. </p> </section> <section id="CD011507-sec-0012"> <h3 class="title" id="CD011507-sec-0012">How the intervention might work</h3> <p>Given these beneficial effects on improving insulin sensitivity, myo‐inositol may be useful for women with gestational diabetes. A retrospective review of 46 pregnant women treated with myo‐inositol compared with 37 controls described it as safe during the pre‐pregnancy and early pregnancy period when used in insulin‐resistant conditions (<a href="./references#CD011507-bbs2-0028" title="D'AnnaR , Di BendettoV , RizzoP , RaffoneE , InterdantoML , CoradoF , et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecological Endocrinology2012;28(6):440-2.">D'Anna 2012</a>). No women reported any side effects of treatment.  </p> </section> <section id="CD011507-sec-0013"> <h3 class="title" id="CD011507-sec-0013">Why it is important to do this review</h3> <p>Gestational diabetes is an increasing problem worldwide. To date, three Cochrane Reviews on the prevention of gestational diabetes have been conducted. In <i>Dietary advice in pregnancy for preventing gestational diabetes mellitus, </i><a href="./references#CD011507-bbs2-0054" title="TieuJ , ShepherdE , MiddletonP , CrowtherCA . Dietary advice in pregnancy for preventing gestational diabetes mellitus. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD006674. [DOI: 10.1002/14651858.CD006674]">Tieu 2017</a> concluded that while a low glycaemic index (GI) diet was beneficial for some outcomes for the mother (lower maternal fasting glucose concentration) and child (reduction in large‐for‐gestational‐age infants, lower ponderal index), the evidence is limited. Similarly, in <i>Exercise for pregnant women for preventing gestational diabetes mellitus,</i> Han and colleagues concluded that there is limited evidence to support exercise during pregnancy for the prevention of glucose intolerance or gestational diabetes (<a href="./references#CD011507-bbs2-0034" title="HanS , CrowtherCA , MiddletonP . Exercise for pregnant women for preventing gestational diabetes mellitus. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD009021. [DOI: 10.1002/14651858.CD009021.pub2]">Han 2012</a>). Bain and colleagues assessed the effects of physical exercise in combination with dietary advice for pregnant women for preventing gestational diabetes, and health consequences for the mother and her infant/child (<a href="./references#CD011507-bbs2-0022" title="BainE , CraneM , TieuJ , HanS , CrowtherCA , MiddletonP . Diet and exercise interventions for preventing gestational diabetes mellitus. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD010443. [DOI: 10.1002/14651858.CD010443.pub2]">Bain 2015</a>). They found no clear differences in outcomes between women receiving diet and exercise interventions compared with those receiving no intervention. Thus, identification of effective preventive measures for gestational diabetes remains of great importance. This is an update of a review first published in 2015, that found that myo‐inositol taken during pregnancy may prevent the development of gestational diabetes, but further trials were required (<a href="./references#CD011507-bbs2-0062" title="CrawfordTJ , CrowtherCA , AlsweilerJ , BrownJ . Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD011507. [DOI: 10.1002/14651858.CD011507.pub2]">Crawford 2015</a>). Since then further trials have been published that may be eligible for inclusion in this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011507-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011507-sec-0014"></div> <p>To assess if antenatal dietary supplementation with myo‐inositol is safe and effective, for the mother and fetus, in preventing gestational diabetes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011507-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011507-sec-0015"></div> <section id="CD011507-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011507-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included published and unpublished randomised controlled trials (RCTs) including conference abstracts assessing the effects of myo‐inositol for the prevention of gestational diabetes. We planned to include cluster‐RCTs, but we did not identify any. We excluded quasi‐randomised trials and cross‐over trials. </p> </section> <section id="CD011507-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included pregnant women but excluded women with pre‐existing type 1 or type 2 diabetes. </p> </section> <section id="CD011507-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any dose of myo‐inositol in pregnancy, alone or in a combination preparation, for the purpose of preventing gestational diabetes. We included studies where such intervention was compared with no treatment, placebo or another intervention. </p> </section> <section id="CD011507-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Studies that met the above inclusion criteria were included regardless of whether they reported on the following outcomes for the review. </p> <section id="CD011507-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD011507-sec-0022"> <h6 class="title">Maternal outcomes</h6> <p> <ul id="CD011507-list-0002"> <li> <p>Gestational diabetes (diagnostic criteria as defined in individual studies)</p> </li> <li> <p>Hypertensive disorders of pregnancy (including pre‐eclampsia, eclampsia, pregnancy‐induced hypertension) </p> </li> </ul> </p> </section> <section id="CD011507-sec-0023"> <h6 class="title">Neonatal outcomes</h6> <p> <ul id="CD011507-list-0003"> <li> <p>Large‐for‐gestational age (birthweight greater than the 90th centile; or as defined by individual study) </p> </li> <li> <p>Perinatal mortality (stillbirth and neonatal mortality)</p> </li> <li> <p>Mortality or morbidity composite (variously defined by trials, e.g. infant death, shoulder dystocia, bone fracture or nerve palsy) </p> </li> </ul> </p> </section> </section> <section id="CD011507-sec-0024"> <h5 class="title">Secondary outcomes</h5> <section id="CD011507-sec-0025"> <h6 class="title">Maternal outcomes</h6> <p> <ul id="CD011507-list-0004"> <li> <p>Caesarean section</p> </li> <li> <p>Placental abruption</p> </li> <li> <p>Induction of labour</p> </li> <li> <p>Perineal trauma</p> </li> <li> <p>Postpartum hemorrhage</p> </li> <li> <p>Postpartum infection</p> </li> <li> <p>Weight gain during pregnancy</p> </li> <li> <p>Adherence to the intervention (as defined by study authors)</p> </li> <li> <p>Behaviour changes associated with the intervention (as defined by study authors)</p> </li> <li> <p>Relevant biomarker changes associated with the intervention (e.g. adiponectin, free fatty acids, triglycerides, high‐density lipoproteins (HDL), low‐density lipoproteins (LDL), insulin) </p> </li> <li> <p>Sense of well‐being and quality of life</p> </li> <li> <p>Views of the intervention</p> </li> <li> <p>Breastfeeding (e.g. at discharge, six weeks postpartum)</p> </li> <li> <p>Adverse effects of intervention</p> </li> </ul> </p> </section> <section id="CD011507-sec-0026"> <h6 class="title">Long‐term maternal outcomes</h6> <p> <ul id="CD011507-list-0005"> <li> <p>Postnatal depression</p> </li> <li> <p>Postnatal weight retention or return to pre‐pregnancy weight</p> </li> <li> <p>Body mass index (BMI)</p> </li> <li> <p>Gestational diabetes in a subsequent pregnancy</p> </li> <li> <p>Type 1 diabetes mellitus</p> </li> <li> <p>Type 2 diabetes mellitus</p> </li> <li> <p>Impaired glucose tolerance</p> </li> <li> <p>Cardiovascular health (as defined by trialists, including blood pressure (BP), hypertension, cardiovascular disease, metabolic syndrome) </p> </li> </ul> </p> </section> <section id="CD011507-sec-0027"> <h6 class="title">Infant outcomes</h6> <p> <ul id="CD011507-list-0006"> <li> <p>Stillbirth</p> </li> <li> <p>Neonatal mortality</p> </li> <li> <p>Gestational age at birth</p> </li> <li> <p>Preterm birth (less than 37 weeks' gestation and less than 32 weeks' gestation)</p> </li> <li> <p>Apgar score (less than seven at five minutes)</p> </li> <li> <p>Macrosomia</p> </li> <li> <p>Small‐for‐gestational age</p> </li> <li> <p>Birthweight and birthweight z‐score</p> </li> <li> <p>Head circumference and head circumference z‐score</p> </li> <li> <p>Length and length z‐score</p> </li> <li> <p>Ponderal index</p> </li> <li> <p>Adiposity</p> </li> <li> <p>Shoulder dystocia</p> </li> <li> <p>Bone fracture</p> </li> <li> <p>Nerve palsy</p> </li> <li> <p>Respiratory distress syndrome</p> </li> <li> <p>Hypoglycaemia (variously defined)</p> </li> <li> <p>Hyperbilirubinaemia</p> </li> </ul> </p> </section> <section id="CD011507-sec-0028"> <h6 class="title">Childhood outcomes</h6> <p> <ul id="CD011507-list-0007"> <li> <p>Weight and weight z‐score</p> </li> <li> <p>Height and height z‐score</p> </li> <li> <p>Head circumference and head circumference z‐score</p> </li> <li> <p>Adiposity (e.g. as measured by BMI, skinfold thickness)</p> </li> <li> <p>Blood pressure</p> </li> <li> <p>Type 1 diabetes mellitus</p> </li> <li> <p>Type 2 diabetes mellitus</p> </li> <li> <p>Impaired glucose tolerance</p> </li> <li> <p>Dyslipidaemia or metabolic syndrome</p> </li> <li> <p>Neurodisability</p> </li> <li> <p>Educational achievement</p> </li> </ul> </p> </section> <section id="CD011507-sec-0029"> <h6 class="title">Adulthood outcomes</h6> <p> <ul id="CD011507-list-0008"> <li> <p>Weight</p> </li> <li> <p>Height</p> </li> <li> <p>Adiposity (e.g. as measured by BMI, skinfold thickness)</p> </li> <li> <p>Cardiovascular health (as defined by study authors, including BP, hypertension, cardiovascular disease, metabolic syndrome) </p> </li> <li> <p>Type 1 diabetes mellitus</p> </li> <li> <p>Type 2 diabetes mellitus</p> </li> <li> <p>Impaired glucose tolerance</p> </li> <li> <p>Dyslipidaemia or metabolic syndrome</p> </li> <li> <p>Employment, education and social status/achievement</p> </li> </ul> </p> </section> <section id="CD011507-sec-0030"> <h6 class="title">Health services cost</h6> <p> <ul id="CD011507-list-0009"> <li> <p>Number of hospital or health professional visits (e.g. midwife, obstetrician, physician, dietitian, diabetic nurse) </p> </li> <li> <p>Number of antenatal visits or admissions</p> </li> <li> <p>Length of antenatal stay</p> </li> <li> <p>Neonatal intensive care unit (NICU) admission</p> </li> <li> <p>Length of postnatal stay (mother)</p> </li> <li> <p>Length of postnatal stay (baby)</p> </li> <li> <p>Costs to families associated with the management provided</p> </li> <li> <p>Costs associated with the intervention</p> </li> <li> <p>Cost of maternal care</p> </li> <li> <p>Cost of offspring care</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011507-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <p>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group. </p> <section id="CD011507-sec-0032"> <h4 class="title">Electronic searches</h4> <p>We searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (17 March 2022). </p> <p>The Register is a database containing over 34,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register, including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL, the list of hand searched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a>. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ul id="CD011507-list-0010"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) which includes centralised searches of the WHO International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/" target="_blank">ICTRP</a>); </p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ul> </p> <p>These search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above are reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth Group review topic (or topics) and is then added to the Register.  </p> <p>The Information Specialist searched the Register for this review using this topic number rather than keywords. This results in a more specific search set which has been fully accounted for in the relevant review sections (Included, Excluded, Awaiting Classification or Ongoing). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO ICTRP for unpublished, planned and ongoing trial reports (17 March 2022). The search terms used are given in <a href="./appendices#CD011507-sec-0136">Appendix 1</a>. </p> </section> <section id="CD011507-sec-0033"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of retrieved studies.</p> <p>We did not apply any language or date restrictions.</p> </section> </section> <section id="CD011507-sec-0034"> <h3 class="title" id="CD011507-sec-0034">Data collection and analysis</h3> <section id="CD011507-sec-0035"> <h4 class="title">Selection of studies</h4> <p>Three review authors (SM, LL and CC) independently assessed all potential studies identified from the search strategy for inclusion. We resolved any disagreement through discussion. We created a study flow diagram to map out the number of records identified, included and excluded (<a href="#CD011507-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011507-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for updated review" data-id="CD011507-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for updated review</p> </div> </div> </div> <section id="CD011507-sec-0036"> <h5 class="title">Screening eligible studies for scientific integrity or trustworthiness</h5> <p>Two review authors evaluated all studies that initially met our inclusion criteria against predefined criteria to determine which studies, based on available information, were deemed to be sufficiently untrustworthy to be excluded. We used the following criteria. </p> <section id="CD011507-sec-0037"> <h6 class="title">Research governance</h6> <p> <ul id="CD011507-list-0011"> <li> <p>No prospective trial registration for studies published after 2010 without plausible explanation. </p> </li> <li> <p>When requested, study authors refused to share the protocol and or ethics approval letter. </p> </li> <li> <p>Study authors refused to engage in communication with the Cochrane Review authors.</p> </li> <li> <p>Study authors refused to provide individual patient data (IPD) upon request with no justifiable reason. </p> </li> </ul> </p> </section> <section id="CD011507-sec-0038"> <h6 class="title">Baseline characteristics</h6> <p>Characteristics of the study participants being too similar (distribution of mean (SD) excessively narrow or excessively wide, as noted by <a href="./references#CD011507-bbs2-0024" title="CarlisleJB . Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trial in anaesthetic and general medical journals. Anaesthesia2017;72:944-95.">Carlisle 2017</a>). </p> </section> <section id="CD011507-sec-0039"> <h6 class="title">Feasibility</h6> <p> <ul id="CD011507-list-0012"> <li> <p>Implausible numbers (e.g. 500 women with severe cholestasis of pregnancy recruited in 12 months). </p> </li> <li> <p>(Close to) zero losses to follow‐up without plausible explanation.</p> </li> </ul> </p> <p><b>Results</b> </p> <p> <ul id="CD011507-list-0013"> <li> <p>Implausible results (e.g. massive risk reduction for main outcomes with small sample size). </p> </li> <li> <p>Unexpectedly even numbers of women ‘randomised’ including a mismatch between the numbers and the methods (e.g. if they say no blocking was used but still end up with equal numbers, or they say they used blocks of four, but the final numbers differ by six). </p> </li> </ul> </p> <p>We excluded studies assessed as being potentially high risk. Where a study was classified as high risk for one or more of the above criteria, we attempted to contact the study authors to address any possible lack of information or concerns. If adequate information remained unavailable, we kept the study in <a href="./references#CD011507-bbs1-0003" title="">Studies awaiting classification</a> and we reported the reasons and communications with the study author (or lack of), in detail. </p> <p>The process used is described in <a href="#CD011507-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011507-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Applying the trustworthiness screening tool criteria. TST: Trustworthiness Screening Tool." data-id="CD011507-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Applying the trustworthiness screening tool criteria. TST: Trustworthiness Screening Tool. </p> </div> </div> </div> </section> <section id="CD011507-sec-0040"> <h6 class="title">Abstracts</h6> <p>We only included data from abstracts if, in addition to the trustworthiness assessment, the study authors confirmed in writing that the data to be included in the review had come from the final analysis and would not change. If such information was not available or provided, the study remained in <a href="./references#CD011507-bbs1-0003" title="">Studies awaiting classification</a> (as above). </p> </section> </section> </section> <section id="CD011507-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract data based on the Cochrane Pregnancy and Childbirth Group's data extraction form. For eligible studies, two review authors (SM, LL, JA and CC) independently extracted the data using the agreed form. We resolved discrepancies through discussion. We entered data into Review Manager software (<a href="./references#CD011507-bbs2-0049" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>) and checked for accuracy. When information regarding any of the above was unclear, we attempted to contact study authors of the original reports to provide further details. </p> </section> <section id="CD011507-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group. </p> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011507-bbs2-0035" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.cochrane-handbook.org.">Higgins 2021</a>). We resolved any disagreement by discussion. </p> <section id="CD011507-sec-0043"> <h5 class="title">Random sequence generation (checking for possible selection bias)</h5> <p>For each included study we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD011507-list-0014"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011507-sec-0044"> <h5 class="title">Allocation concealment (checking for possible selection bias)</h5> <p>For each included study we described the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011507-list-0015"> <li> <p>low risk of bias (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias</p> </li> </ul> </p> </section> <section id="CD011507-sec-0045"> <h5 class="title">Blinding of participants and personnel (checking for possible performance bias)</h5> <p>For each included study we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011507-list-0016"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD011507-sec-0046"> <h5 class="title">Blinding of outcome assessment (checking for possible detection bias)</h5> <p>For each included study we described the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods used to blind outcome assessment as:</p> <p> <ul id="CD011507-list-0017"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011507-sec-0047"> <h5 class="title">Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>For each outcome or class of outcomes in each included study, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the study authors, we re‐included missing data in the analyses which we undertook. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011507-list-0018"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomization); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011507-sec-0048"> <h5 class="title">Selective reporting (checking for reporting bias)</h5> <p>For each included study we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD011507-list-0019"> <li> <p>low risk of bias (where it is clear that all the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD011507-sec-0049"> <h5 class="title">Other bias (checking for bias due to problems not covered by the domains above)</h5> <p>For each included study we described any important concerns we have about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD011507-list-0020"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD011507-sec-0050"> <h5 class="title">Overall risk of bias</h5> <p>We made explicit judgments about whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011507-bbs2-0035" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.cochrane-handbook.org.">Higgins 2021</a>). With reference to the domains above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We explored the impact of the level of bias by undertaking sensitivity analyses (see <a href="#CD011507-sec-0063">Sensitivity analysis</a>). </p> </section> </section> <section id="CD011507-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011507-sec-0052"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratios (RR) with 95% confidence intervals (CIs). </p> </section> <section id="CD011507-sec-0053"> <h5 class="title">Continuous data</h5> <p>For continuous data where outcomes were measured on the same scale, we presented the mean difference (MD) with 95% CIs. For studies that measured the same outcome on different scales, we planned to report the standardised mean difference (SMD) and 95% CIs. </p> </section> </section> <section id="CD011507-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011507-sec-0055"> <h5 class="title">Cluster‐RCTs</h5> <p>We did not identify any cluster‐RCTs for inclusion in this review. If we identify cluster‐RCTs for inclusion in future updates of this review, we will include them in the analyses along with individually‐randomised studies. We will make adjustments using the methods described in sections 16.3.4 and 16.3.6 in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011507-bbs2-0035" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.cochrane-handbook.org.">Higgins 2021</a>), using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar study or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. We will consider it reasonable to combine the results from both cluster‐RCTs and individually‐randomised studies if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomization unit is considered to be unlikely. </p> </section> <section id="CD011507-sec-0056"> <h5 class="title">Multiple pregnancy</h5> <p>There may be unit of analysis issues that arise when women randomised have a multiple pregnancy. We present maternal data as per woman randomised and neonatal data as per infant. </p> </section> <section id="CD011507-sec-0057"> <h5 class="title">Multiple arm studies</h5> <p>In future updates of this review, where a study has multiple intervention arms, we will avoid 'double counting' of participants by combining groups to create a single pair‐wise comparison if possible. Where this is not possible, we will split the 'shared' group into two or more groups with smaller sample size and include two or more (reasonably independent) comparisons. </p> </section> </section> <section id="CD011507-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat (ITT) basis; that is, we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether they received the allocated intervention. The denominator for each outcome in each study was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD011507-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if I² was greater than 30% and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. </p> </section> <section id="CD011507-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not undertake investigation of reporting biases because we included only seven studies. In future updates of this review, if 10 or more studies are included in the meta‐analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD011507-sec-0061"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using the Review Manager (RevMan) software (<a href="./references#CD011507-bbs2-0049" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used fixed‐effect meta‐analyses for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect (i.e. where studies were examining the same intervention, and the studies’ populations and methods were judged sufficiently similar). If there was sufficient clinical heterogeneity to suggest that the underlying treatment effects differed between studies, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary, if an average treatment effect across studies was considered clinically meaningful. The random‐effects summary was treated as the average of the range of possible treatment effects, and we discussed the clinical implications of treatment effects differing between studies. If the average treatment effect was not clinically meaningful, we did not combine studies. </p> <p>Where we used random‐effects analyses, we present the results as the average treatment effect with 95% CIs, and the estimates of Tau² and I². </p> </section> <section id="CD011507-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we investigated it using subgroup analyses and sensitivity analyses where data were available. We considered whether an overall summary was meaningful, and if it was, used random‐effects analysis to produce it. </p> <p>We planned to conduct the following subgroup analyses:</p> <p> <ul id="CD011507-list-0021"> <li> <p>women with polycystic ovary syndrome (PCOS) versus women without PCOS;</p> </li> <li> <p>obese women versus non‐obese women;</p> </li> <li> <p>dosage: high versus low dose;</p> </li> <li> <p>myo‐inositol alone or in combination versus non myo‐inositol combination;</p> </li> <li> <p>commencement of myo‐inositol supplementation: pre‐pregnancy versus first trimester.</p> </li> </ul> </p> <p>However, we were unable to split the participant data into subgroups, and none of the included studies commenced supplementation with myo‐inositol pre‐pregnancy. </p> <p>We planned to restrict subgroup analysis to this review's primary outcomes.</p> <p>In future versions of this review, we will assess subgroup differences by interaction tests available within RevMan (<a href="./references#CD011507-bbs2-0049" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We will report the results of subgroup analyses quoting the Chi<sup>2</sup> statistic and P value, and the interaction test I² value. </p> </section> <section id="CD011507-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>We had insufficient studies to conduct sensitivity analysis for this review. If in future updates there are sufficient studies for analysis, and there is evidence of significant heterogeneity for primary outcomes, we will explore heterogeneity by using the quality of the included studies. We will compare studies that have low risk of bias for allocation concealment with those judged to be of unclear or high risk of bias. </p> </section> <section id="CD011507-sec-0064"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of the evidence using the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a>, in order to assess the certainty of the body of evidence relating to the following outcomes for the main comparisons. We produced two summary of findings tables for seven maternal outcomes and seven neonatal, child and adult outcomes.  </p> <section id="CD011507-sec-0065"> <h5 class="title">Maternal</h5> <p> <ul id="CD011507-list-0022"> <li> <p>Gestational diabetes </p> </li> <li> <p>Weight gain during pregnancy</p> </li> <li> <p>Hypertensive disorders of pregnancy (including pre‐eclampsia, eclampsia, and pregnancy‐induced hypertension) </p> </li> <li> <p>Caesarean section</p> </li> <li> <p>Perineal trauma</p> </li> <li> <p>Postnatal depression</p> </li> <li> <p>Development of subsequent type 2 diabetes mellitus</p> </li> </ul> </p> </section> <section id="CD011507-sec-0066"> <h5 class="title">Neonatal, child, adult outcomes</h5> <p> <ul id="CD011507-list-0023"> <li> <p>Large‐for‐gestational age</p> </li> <li> <p>Perinatal mortality (stillbirth and neonatal mortality)</p> </li> <li> <p>Composite of serious neonatal outcomes</p> </li> <li> <p>Neonatal hypoglycaemia (variously defined)</p> </li> <li> <p>Adiposity (e.g. as measured by BMI, skinfold thickness)</p> </li> <li> <p>Diabetes</p> </li> <li> <p>Neurosensory disability</p> </li> </ul> </p> <p>We used the <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5.3 (<a href="./references#CD011507-bbs2-0049" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>) in order to create summary of findings tables. We produced a summary of the intervention effect and a measure of certainty for each of the above outcomes using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence for each outcome. The evidence can be downgraded from 'high certainty' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011507-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011507-sec-0067"></div> <section id="CD011507-sec-0068"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011507-sec-0146" title="">Characteristics of included studies</a>.  </p> <section id="CD011507-sec-0069"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD011507-fig-0001">Figure 1</a>. </p> <p>In the previous version of the review, we included four studies (seven reports) and excluded two studies. The updated search (March 2022) retrieved 28 new study reports after we removed duplicates. We deemed five of these records not relevant based on title and abstract. We assessed the remaining 23 records, plus one report of an ongoing study (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>) in the previous review. We classified seven studies (12 reports) as ongoing trials (<a href="./references#CD011507-bbs2-0013" title="AmaefuleCE , DrymoussiZ , DoddsJ , SweeneyL , PizzoE , DaruJ , et al. Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a protocol for a randomised, placebo-controlled, double-blind pilot trial. BMJ Open2018;8(9):e022831. AmaefuleCE , SweeneyL , ThangaratinamS . Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind multi-centred pilot trial with nested qualitative evaluation. British Journal of Obstetrics and Gynaecology2019;126(S1):26. [CENTRAL: CN-01936587] [EMBASE: 627142813]HeighwayJM , DrymoussiZ , LanzD , ThangaratinamS . Approaches to data cleaning in a pilot study: (EMmY) Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes: a pilot placebo controlled double blind randomised trial. Trials2019;20:10. [CENTRAL: CN-02006813] [EMBASE: 629760350]ISRCTN48872100. Preventing gestational diabetes with myo-inositol supplement. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN48872100 (first received 2018). [CENTRAL: CN-01902369] ">Amaefule 2018</a>; <a href="./references#CD011507-bbs2-0014" title="AsimakopoulosG , PergialiotisV , AnastasiouE , AntsaklisP , TheodoraM , VogiatziE , et al. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. Trials2020;21(1):633. [CENTRAL: CN-02130113] [EMBASE: 144473532] [PMID: 32646482]ISRCTN16142533. Myo-inositol supplementation for the prevention of gestational diabetes. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN16142533 (first received 2017). [CENTRAL: CN-01856278] ">Asimakopoulos 2020</a>; <a href="./references#CD011507-bbs2-0015" title="CTRI/2018/06/014477. A clinical study to assess the potential of myo-d-chiro-inositol in prevention of the development of GDM in pregnant women. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/06/014477 (first received 2018). [CENTRAL: CN-01905638] ">CTRI/2018/06/014477</a>; <a href="./references#CD011507-bbs2-0016" title="IbrahimI , AbdullahiH , FagierY , OrtashiO , TerrangeraA , OkunoyeG . Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial. BMJ Open2022;12(1):e055314. [CENTRAL: CN-02361232] [EMBASE: 636884973]ISRCTN16448440. The study of myo-inositol supplements for reducing the risk of gestational diabetes mellitus [Effect of antenatal dietary Myo-inositol supplementation in women during pregnancy on the incidence of gestational diabetes mellitus (GDM) and fetal outcome: a randomized controlled trial]. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN16448440 (first received 2021). [CENTRAL: CN-02279815] ">Ibrahim 2022</a>; <a href="./references#CD011507-bbs2-0017" title="IRCT20120826010664N4. The effect of myoinositol supplementation on the prevention of gestational diabetes mellitus. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120826010664N4 (first received 2019). [CENTRAL: CN-01971330] ">IRCT20120826010664N4</a>; <a href="./references#CD011507-bbs2-0018" title="NCT04801485. Myo-inositol in prevention of gestational diabetes mellitus in China [Myo-inositol in prevention of gestational diabetes mellitus in high risk pregnant women in China]. clinicaltrials.gov/show/NCT04801485 (first received 17 March 2021). [CENTRAL: CN-02242297] ">NCT04801485</a>; <a href="./references#CD011507-bbs2-0019" title="NL7799. Mypp-trial: myo-inositol supplementation to prevent pregnancy complications in women with polycystic ovary syndrome: a multicentre double-blind randomised controlled trial. www.who.int/trialsearch/Trial2.aspx?TrialID=NL7799 (first received 2019). [CENTRAL: CN-01971105] ">NL7799</a>). We excluded two studies as the participants did not meet the inclusion criteria of the review (<a href="./references#CD011507-bbs2-0008" title="CelentanoC , MatarrelliB , PavoneG , VitacolonnaE , MatteiPA , BerghellaV , et al. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. Journal of Maternal Fetal and Neonatal Medicine2020;33(5):743-51. ">Celentano 2020</a>; <a href="./references#CD011507-bbs2-0010" title='GodfreyKM , CutfieldW , Chan S-Y, BakerPN , Chong Y-S, ArisIB , et al. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials2017;18(1):131. '>Godfrey 2017</a>). We considered four studies (8 records) as eligible for inclusion in the updated review (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Facchinetti 2013 was included in the previous version of this review, but we confirmed with the authors that Facchinetti 2013 is an interim report of <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>. We classified one study (two reports) (<a href="./references#CD011507-bbs2-0012" title="EsmaeilzadehS , GhadimiR , MashayekhamiriS , DelavarMA , BasiratZ . The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial; 16 April 2021, PREPRINT (Version 1). www.researchsquare.com/article/rs-260476/v1 (accessed April 2021). [DOI: 10.21203/rs.3.rs-260476/v1]IRCT20160208026446N2. The impact of myo-inositol supplementation to gestational diabetes in overweight pregnant women. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20160208026446N2 (first received 2017). [CENTRAL: CN-01903667] ">Esmaeilzadeh 2021</a>) as awaiting classification whilst awaiting further details. Therefore, we included seven studies in the updated review. </p> <section id="CD011507-sec-0070"> <h5 class="title">Screening eligible studies for trustworthiness</h5> <p>From the seven eligible studies identified from the search, we judged that all studies met our criteria for trustworthiness. </p> </section> </section> <section id="CD011507-sec-0071"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD011507-sec-0146" title="">Characteristics of included studies</a>. </p> <section id="CD011507-sec-0072"> <h5 class="title">Study design</h5> <p>We included seven RCTs (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). </p> </section> <section id="CD011507-sec-0073"> <h5 class="title">Setting</h5> <p>Six studies were conducted in Italy (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>) and one study was conducted in Ireland (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). The included studies were conducted between 2010 and 2018.   </p> </section> <section id="CD011507-sec-0074"> <h5 class="title">Participants</h5> <p>All studies were conducted in pregnant women. Gestational age at study entry was 10 to 16 weeks in one study (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>); 12 to 13 weeks in four studies (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>); 13 to 24 weeks in one study (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>); and 24 to 28 weeks in another study (<a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>). Six studies were on women with a BMI less than 30 kg/m<sup>2</sup> (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>) while one study was on obese women with a BMI greater 30 kg/m<sup>2</sup> (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>). Three studies included women exclusively of white ethnicity (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). An inclusion criterion in <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> was a first‐degree relative with type 2 diabetes. Women with pre‐existing diabetes mellitus were excluded from all included studies </p> <p>Five studies (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>) used the International Association of Diabetes and Pregnancy Study Groups (<a href="./references#CD011507-bbs2-0036" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676-82.">IADPSG 2010</a>) to diagnose GDM while the two studies (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>) used the Italian Society of Diabetology criteria. </p> <p>Groups were comparable at baseline for age, parity and BMI in <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a> and <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>. In <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>, the participants were comparable between groups at baseline for maternal age, BMI and gestational age at the commencement of treatment. In <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>, groups were comparable at baseline for age and haematological parameters. <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>, <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>, and <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> included women exclusively of Caucasian ethnicity. An inclusion criterion in <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> was a first‐degree relative with type 2 diabetes. Women with pre‐existing diabetes mellitus were excluded from all included studies. </p> </section> <section id="CD011507-sec-0075"> <h5 class="title">Intervention</h5> <p>The following doses of myo‐inositol were reported.</p> <p> <ul id="CD011507-list-0024"> <li> <p>4 g myo‐inositol, 400 mcg folic acid daily in divided doses (2 g myo‐inositol plus 200 mcg folic acid twice a day) (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>) </p> </li> <li> <p>1100 mg myo‐inositol, 27.6 mg C‐chiro‐inositol, 400 mcg folic acid per day (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>) </p> </li> <li> <p>2 g myo‐inositol, 400 mg D‐chiro‐inositol, 400 mcg folic acid and 10 mg manganese per day in one dose (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>) </p> </li> <li> <p>200 mg myo‐inositol, 500 mg D‐chiro‐inositol, 80 mg of Revifast (<a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>) </p> </li> </ul> </p> </section> <section id="CD011507-sec-0076"> <h5 class="title">Comparison</h5> <p>The following comparisons were reported.</p> <p> <ul id="CD011507-list-0025"> <li> <p>200 mcg folic acid (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>) </p> </li> <li> <p>400 mcg folic acid (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>) </p> </li> <li> <p>The authors stated women received placebo but did not state what the placebo was (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>). </p> </li> </ul> </p> <p>One study provided nutritional and lifestyle counselling to women in both the treatment and control groups (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>). None of the other included studies reported this. </p> <section id="CD011507-sec-0077"> <h6 class="title">Diagnostic criteria used to diagnose GDM</h6> <p>International Association of Diabetes and Pregnancy Study Groups (<a href="./references#CD011507-bbs2-0036" title="International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care2010;33(3):676-82.">IADPSG 2010</a>): <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>. </p> <p>Italian Society of Diabetology: <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>. </p> </section> </section> <section id="CD011507-sec-0078"> <h5 class="title">Outcomes</h5> <p>Five studies reported on gestational diabetes and provided fasting, one‐ and two‐hour blood glucose results (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). One study reported on gestational diabetes (<a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>) but did not provide blood glucose results. Five studies reported hypertensive disorders of pregnancy (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). Five studies reported on adverse effects of intervention (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Four studies reported a number of maternal and infant outcomes such as caesarean section, gestational age at birth, preterm birth, macrosomia, birthweight, neonatal hypoglycaemia, and shoulder dystocia  (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Four trials reported on weight gain during pregnancy (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Three studies reported on the use of insulin (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Two studies reported on respiratory distress syndrome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). Two studies reported on relevant biomarker changes associated with the intervention (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>). Only one study reported on the following maternal and neonatal outcomes: postpartum hemorrhage, adherence to the intervention, perineal trauma, large for gestation age, small for gestational age, nerve palsy, neonatal hyperbilirubinemia and admission to neonatal intensive care unit or special care baby unit (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). </p> </section> <section id="CD011507-sec-0079"> <h5 class="title">Funding sources</h5> <p>Two studies reported no funding source, with participants buying their own supplements (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> reported that they did not receive any specific grant. Two studies did not state the source of funding (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> was funded by a grant from Messina University, Italy. <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> was supported by the Coombe Women &amp; Infants University Hospital, Ireland and the food supplement was provided at no cost from Lo.Li. Pharma. <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a> reported the research did not receive a specific grant from any funding agency in the public, commercial, or not‐for‐profit sectors. All seven studies reported that none of the authors had any potential financial conflicts of interest (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>).  </p> </section> <section id="CD011507-sec-0080"> <h5 class="title">Ongoing studies</h5> <p>See <a href="./references#CD011507-sec-0149" title="">Characteristics of ongoing studies</a>. </p> <p>One record of an ongoing study from the previous version has now been added to the included studies (Farren 2013). In this update, seven ongoing studies (12 records) have been identified for potential inclusion when published (<a href="./references#CD011507-bbs2-0013" title="AmaefuleCE , DrymoussiZ , DoddsJ , SweeneyL , PizzoE , DaruJ , et al. Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a protocol for a randomised, placebo-controlled, double-blind pilot trial. BMJ Open2018;8(9):e022831. AmaefuleCE , SweeneyL , ThangaratinamS . Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind multi-centred pilot trial with nested qualitative evaluation. British Journal of Obstetrics and Gynaecology2019;126(S1):26. [CENTRAL: CN-01936587] [EMBASE: 627142813]HeighwayJM , DrymoussiZ , LanzD , ThangaratinamS . Approaches to data cleaning in a pilot study: (EMmY) Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes: a pilot placebo controlled double blind randomised trial. Trials2019;20:10. [CENTRAL: CN-02006813] [EMBASE: 629760350]ISRCTN48872100. Preventing gestational diabetes with myo-inositol supplement. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN48872100 (first received 2018). [CENTRAL: CN-01902369] ">Amaefule 2018</a>; <a href="./references#CD011507-bbs2-0014" title="AsimakopoulosG , PergialiotisV , AnastasiouE , AntsaklisP , TheodoraM , VogiatziE , et al. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. Trials2020;21(1):633. [CENTRAL: CN-02130113] [EMBASE: 144473532] [PMID: 32646482]ISRCTN16142533. Myo-inositol supplementation for the prevention of gestational diabetes. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN16142533 (first received 2017). [CENTRAL: CN-01856278] ">Asimakopoulos 2020</a>; <a href="./references#CD011507-bbs2-0015" title="CTRI/2018/06/014477. A clinical study to assess the potential of myo-d-chiro-inositol in prevention of the development of GDM in pregnant women. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/06/014477 (first received 2018). [CENTRAL: CN-01905638] ">CTRI/2018/06/014477</a>; <a href="./references#CD011507-bbs2-0016" title="IbrahimI , AbdullahiH , FagierY , OrtashiO , TerrangeraA , OkunoyeG . Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial. BMJ Open2022;12(1):e055314. [CENTRAL: CN-02361232] [EMBASE: 636884973]ISRCTN16448440. The study of myo-inositol supplements for reducing the risk of gestational diabetes mellitus [Effect of antenatal dietary Myo-inositol supplementation in women during pregnancy on the incidence of gestational diabetes mellitus (GDM) and fetal outcome: a randomized controlled trial]. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN16448440 (first received 2021). [CENTRAL: CN-02279815] ">Ibrahim 2022</a>; <a href="./references#CD011507-bbs2-0017" title="IRCT20120826010664N4. The effect of myoinositol supplementation on the prevention of gestational diabetes mellitus. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120826010664N4 (first received 2019). [CENTRAL: CN-01971330] ">IRCT20120826010664N4</a>; <a href="./references#CD011507-bbs2-0018" title="NCT04801485. Myo-inositol in prevention of gestational diabetes mellitus in China [Myo-inositol in prevention of gestational diabetes mellitus in high risk pregnant women in China]. clinicaltrials.gov/show/NCT04801485 (first received 17 March 2021). [CENTRAL: CN-02242297] ">NCT04801485</a>; <a href="./references#CD011507-bbs2-0019" title="NL7799. Mypp-trial: myo-inositol supplementation to prevent pregnancy complications in women with polycystic ovary syndrome: a multicentre double-blind randomised controlled trial. www.who.int/trialsearch/Trial2.aspx?TrialID=NL7799 (first received 2019). [CENTRAL: CN-01971105] ">NL7799</a>). </p> <p><a href="./references#CD011507-bbs2-0013" title="AmaefuleCE , DrymoussiZ , DoddsJ , SweeneyL , PizzoE , DaruJ , et al. Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a protocol for a randomised, placebo-controlled, double-blind pilot trial. BMJ Open2018;8(9):e022831. AmaefuleCE , SweeneyL , ThangaratinamS . Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind multi-centred pilot trial with nested qualitative evaluation. British Journal of Obstetrics and Gynaecology2019;126(S1):26. [CENTRAL: CN-01936587] [EMBASE: 627142813]HeighwayJM , DrymoussiZ , LanzD , ThangaratinamS . Approaches to data cleaning in a pilot study: (EMmY) Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes: a pilot placebo controlled double blind randomised trial. Trials2019;20:10. [CENTRAL: CN-02006813] [EMBASE: 629760350]ISRCTN48872100. Preventing gestational diabetes with myo-inositol supplement. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN48872100 (first received 2018). [CENTRAL: CN-01902369] ">Amaefule 2018</a> will compare outcomes of participants who take 2 g of myo‐inositol twice daily from 12 + 0 to 15 + 6 weeks’ gestational age until delivery with those who take an identical placebo at the same dose and duration. Their participants will be pregnant women with a singleton pregnancy recruited from 15 + 6 weeks of gestation.  <a href="./references#CD011507-bbs2-0014" title="AsimakopoulosG , PergialiotisV , AnastasiouE , AntsaklisP , TheodoraM , VogiatziE , et al. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. Trials2020;21(1):633. [CENTRAL: CN-02130113] [EMBASE: 144473532] [PMID: 32646482]ISRCTN16142533. Myo-inositol supplementation for the prevention of gestational diabetes. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN16142533 (first received 2017). [CENTRAL: CN-01856278] ">Asimakopoulos 2020</a> aims to compare outcomes between participants who take 4 g of myo‐inositol and 400 mcg of folic acid daily from 11 to 13 + 6 to 26 to 28 weeks of gestation with those who take 400 mcg of folic acid daily for the same duration. Their participants will not have pre‐existing impaired glucose tolerance and will have a singleton pregnancy. <a href="./references#CD011507-bbs2-0015" title="CTRI/2018/06/014477. A clinical study to assess the potential of myo-d-chiro-inositol in prevention of the development of GDM in pregnant women. www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/06/014477 (first received 2018). [CENTRAL: CN-01905638] ">CTRI/2018/06/014477</a> aims to compare outcomes between participants who take myo‐d‐chiro inositol and vitamin D3 sachets twice daily in water and those who take placebo and vitamin D3 sachets twice daily. Their participants will have a BMI ≤ 35. <a href="./references#CD011507-bbs2-0016" title="IbrahimI , AbdullahiH , FagierY , OrtashiO , TerrangeraA , OkunoyeG . Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial. BMJ Open2022;12(1):e055314. [CENTRAL: CN-02361232] [EMBASE: 636884973]ISRCTN16448440. The study of myo-inositol supplements for reducing the risk of gestational diabetes mellitus [Effect of antenatal dietary Myo-inositol supplementation in women during pregnancy on the incidence of gestational diabetes mellitus (GDM) and fetal outcome: a randomized controlled trial]. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN16448440 (first received 2021). [CENTRAL: CN-02279815] ">Ibrahim 2022</a> aims to compare outcomes in pregnant women who will either take myo‐inositol supplementation or a placebo, with all participants completing at least 12 weeks of supplementation prior to undertaking the OGTT at 24 to 28 weeks. <a href="./references#CD011507-bbs2-0017" title="IRCT20120826010664N4. The effect of myoinositol supplementation on the prevention of gestational diabetes mellitus. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120826010664N4 (first received 2019). [CENTRAL: CN-01971330] ">IRCT20120826010664N4</a> will analyse differences in outcomes of their participants who take 2 g of myo‐inositol and 200 mcg of folic acid twice daily from 14 to 28 weeks gestation with those who take only 200 mcg folic acid twice daily. They will recruit participants they define to have a high risk of developing gestational diabetes.  <a href="./references#CD011507-bbs2-0018" title="NCT04801485. Myo-inositol in prevention of gestational diabetes mellitus in China [Myo-inositol in prevention of gestational diabetes mellitus in high risk pregnant women in China]. clinicaltrials.gov/show/NCT04801485 (first received 17 March 2021). [CENTRAL: CN-02242297] ">NCT04801485</a> will examine outcomes in women considered at high risk of gestational diabetes who will either take myo‐inositol 1 gram per day as well as health guidance about diet and exercise or a placebo and the same health guidance. <a href="./references#CD011507-bbs2-0019" title="NL7799. Mypp-trial: myo-inositol supplementation to prevent pregnancy complications in women with polycystic ovary syndrome: a multicentre double-blind randomised controlled trial. www.who.int/trialsearch/Trial2.aspx?TrialID=NL7799 (first received 2019). [CENTRAL: CN-01971105] ">NL7799</a> will examine outcomes in pregnant women with confirmed PCOS who take 4 g myo‐inositol in addition to folic acid supplement, twice daily throughout pregnancy and those with PCOS who take the standard dose of folic acid without the myo‐inositol supplement. </p> <p>(See Ongoing studies).</p> </section> </section> <section id="CD011507-sec-0081"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD011507-sec-0147" title="">Characteristics of excluded studies</a>. </p> <p>In the previous version of this review, two studies were excluded (<a href="./references#CD011507-bbs2-0009" title="CorradoF , D'AnnaR , Di ViesteG , GiordanoD , PintaudiB , SantamariaA , et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabetic Medicine2011;28(8):972-5. ">Corrado 2011</a>; <a href="./references#CD011507-bbs2-0011" title="MatarrelliB , VitacolonnaE , D'angeloM , PavoneG , MatteiPA , LiberatiM , et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2013;26(10):967-72. ">Matarrelli 2013</a>). These studies were ineligible as they used myo‐inositol as a treatment for women already diagnosed with gestational diabetes rather than as a preventative intervention. </p> <p>In this update, we excluded two studies (<a href="./references#CD011507-bbs2-0008" title="CelentanoC , MatarrelliB , PavoneG , VitacolonnaE , MatteiPA , BerghellaV , et al. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. Journal of Maternal Fetal and Neonatal Medicine2020;33(5):743-51. ">Celentano 2020</a>; <a href="./references#CD011507-bbs2-0010" title='GodfreyKM , CutfieldW , Chan S-Y, BakerPN , Chong Y-S, ArisIB , et al. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials2017;18(1):131. '>Godfrey 2017</a>) as their participants did not meet the inclusion criteria for this review. <a href="./references#CD011507-bbs2-0008" title="CelentanoC , MatarrelliB , PavoneG , VitacolonnaE , MatteiPA , BerghellaV , et al. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. Journal of Maternal Fetal and Neonatal Medicine2020;33(5):743-51. ">Celentano 2020</a> recruited pregnant women with elevated fasting glucose levels (&gt; 92 mg/dL and &lt; 126 mg/dL) which may include women with pre‐gestational diabetes. <a href="./references#CD011507-bbs2-0010" title='GodfreyKM , CutfieldW , Chan S-Y, BakerPN , Chong Y-S, ArisIB , et al. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials2017;18(1):131. '>Godfrey 2017</a> did not recruit pregnant women to their study but recruited women prior to conception.   </p> </section> </section> <section id="CD011507-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias for most domains were low. See <a href="#CD011507-fig-0003">Figure 3</a> and <a href="#CD011507-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD011507-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011507-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD011507-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011507-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD011507-sec-0083"> <h4 class="title">Allocation</h4> <p>We judged all seven included studies to be at low risk of selection bias for random allocation. Four studies used a computer‐generated random sequence (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>), two used a random number table (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>), and randomisation was carried out by an independent statistician in the other study (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). </p> <p>We judged five studies to be at low risk of selection bias for allocation concealment (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). In three studies, allocation was assigned by a centralised contact who was independent of the recruitment process (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>). Two studies used sealed opaque and sequentially numbered envelopes (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). We judged two studies to be at unclear risk of bias as allocation concealment was not reported (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>).  </p> </section> <section id="CD011507-sec-0084"> <h4 class="title">Blinding</h4> <section id="CD011507-sec-0085"> <h5 class="title">Performance bias</h5> <p>We deemed two studies to be at unclear risk of performance bias as although participants were blinded, the clinicians involved were aware of the treatment allocation (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>). The remaining five studies were open‐label, and we therefore judged them to be at high risk of performance bias (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). </p> </section> <section id="CD011507-sec-0086"> <h5 class="title">Detection bias</h5> <p>We judged three studies to be at low risk of detection bias as outcome assessors were blinded to allocation group (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>). We judged <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> and <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a> as unclear risk due to inadequate reporting of blinding of outcome assessors. In <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>, whilst the outcome of incidence of gestational diabetes was diagnosed by a blood test and unlikely to be affected by blinding, other outcomes such as neonatal respiratory distress syndrome are more subjective and may be impacted by knowledge of treatment group. We judged the remaining two studies to be at high risk of detection bias as they were open‐label (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). </p> </section> </section> <section id="CD011507-sec-0087"> <h4 class="title">Incomplete outcome data</h4> <p>We judged four studies to be at low risk of attrition bias as losses to follow up were low (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). In <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>, there was a 10.5% overall loss to follow‐up but study authors provided a detailed explanation. We judged two studies to be at unclear risk of attrition bias (<a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). In <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a> randomisation and allocation were conducted after excluding six participants, but the three participants who left the study after the first visit were not treated as lost to follow‐up. Analysis was conducted on the remaining 104 women. <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> reported a 10.8% overall loss but did not provide a detailed consort flow diagram. Finally, we judged <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a> to be at high risk of attrition bias due to 26% overall attrition (17 women excluded from final analysis). Seven women left the study spontaneously but their group allocation or reasons for withdrawing were not stated.  </p> </section> <section id="CD011507-sec-0088"> <h4 class="title">Selective reporting</h4> <p>We judged five studies to be at low risk of reporting bias as all pre‐specified outcome measures were reported (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). We judged <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> to be at low risk of reporting bias as all assessed outcome were reported, one outcome was pre‐specified but was not assessed. We judged <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> to be at unclear risk of reporting bias as not all outcomes specified in the methodology section were reported. </p> </section> <section id="CD011507-sec-0089"> <h4 class="title">Other potential sources of bias</h4> <p>We judged all included studies as being at low risk of other bias. The authors of all included studies declared no potential conflicts of interest. </p> </section> </section> <section id="CD011507-sec-0090"> <h3 class="title" id="CD011507-sec-0090">Effects of interventions</h3> <p>See: <a href="./full#CD011507-tbl-0001"><b>Summary of findings 1</b> Myo‐inositol for preventing gestational diabetes: maternal outcomes</a>; <a href="./full#CD011507-tbl-0002"><b>Summary of findings 2</b> Myo‐inositol for preventing gestational diabetes: infant, child and adult outcomes</a> </p> <p>The certainty of the evidence of the included studies is summarised in the <a href="./full#CD011507-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD011507-tbl-0002">summary of findings Table 2</a> for the pre‐specified outcomes of this review. </p> <section id="CD011507-sec-0091"> <h4 class="title">Myo‐inositol versus placebo</h4> <p>All seven included studies compared myo‐inositol and placebo (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). </p> <section id="CD011507-sec-0092"> <h5 class="title">Maternal primary outcomes</h5> <section id="CD011507-sec-0093"> <h6 class="title">Gestational diabetes </h6> <p>Six studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>: <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Meta‐analysis showed that supplementation of myo‐inositol may reduce the incidence of gestational diabetes compared with placebo (risk ratio (RR) 0.53, 95% confidence interval (CI) 0.31 to 0.90; 1140 women; very low‐certainty evidence; <a href="./references#CD011507-fig-0005" title="">Analysis 1.1</a>). Caution is required when interpreting the data due to significant heterogeneity (I<sup>2</sup> = 71%). The difference is most likely due to differences in the study populations. <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> included only obese pregnant women while <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>, <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a> and <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> recruited overweight women. <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> and <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> recruited women with a family history of type 1 or type 2 diabetes in a first‐degree relative. Nutritional and lifestyle counselling was provided to both the intervention and control groups in <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>, but was not reported as being provided in the other studies. </p> <p>Five studies reported on blood glucose concentrations at the time of the diagnostic 75 g OGCT for GDM at 24 to 28 weeks' gestation. Myo‐inositol may be associated with a reduction in blood glucose concentrations compared to placebo. </p> <p> <ul id="CD011507-list-0026"> <li> <p>Fasting: mean difference (MD) ‐0.14 mmol/L, 95% CI ‐0.21 to ‐0.07; 1071 women; <a href="./references#CD011507-fig-0006" title="">Analysis 1.2</a>). </p> </li> <li> <p>One hour: MD ‐0.34 mmol/L, 95% CI ‐0.55 to ‐0.14; 1071 women; <a href="./references#CD011507-fig-0007" title="">Analysis 1.3</a>. </p> </li> <li> <p>Two hours: MD ‐0.38mmol/L, 95% CI ‐0.77 to 0.01; 1071 women; <a href="./references#CD011507-fig-0008" title="">Analysis 1.4</a>. </p> </li> </ul> </p> </section> <section id="CD011507-sec-0094"> <h6 class="title">Hypertensive disorders of pregnancy (including pre‐eclampsia, eclampsia, pregnancy‐induced hypertension) </h6> <p>Five studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Meta‐analysis showed that myo‐inositol may reduce the incidence of gestational hypertension (RR 0.34, 95% CI 0.19 to 0.61; 1052 women; low‐certainty evidence; <a href="./references#CD011507-fig-0009" title="">Analysis 1.5</a>).   </p> </section> </section> <section id="CD011507-sec-0095"> <h5 class="title">Infant primary outcomes</h5> <section id="CD011507-sec-0096"> <h6 class="title">Large‐for‐gestational‐age</h6> <p><a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> reported data on the primary neonatal outcome of large‐for‐gestational‐age and showed no difference between myo‐inositol and placebo (RR 1.40, 95% CI 0.65 to 3.02; 234 infants; low‐certainty evidence; <a href="./references#CD011507-fig-0010" title="">Analysis 1.6</a>).  </p> </section> <section id="CD011507-sec-0097"> <h6 class="title">Perinatal mortality</h6> <p>None of the included studies reported data on this outcome.</p> </section> <section id="CD011507-sec-0098"> <h6 class="title">Mortality or morbidity composite (variously defined by trials, e.g. infant death, shoulder dystocia, bone fracture or nerve palsy) </h6> <p>None of the included studies reported data on this outcome.</p> </section> </section> <section id="CD011507-sec-0099"> <h5 class="title">Maternal secondary outcomes</h5> <section id="CD011507-sec-0100"> <h6 class="title">Caesarean section</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed that myo‐inositol resulted in little to no effect in caesarean section rate (RR 0.91, 95% CI 0.77 to 1.07; 829 women; low‐certainty evidence; <a href="./references#CD011507-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD011507-sec-0101"> <h6 class="title">Weight gain during pregnancy</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Meta‐analysis showed that myo‐inositol resulted in little to no effect on weight gain during pregnancy compared to placebo (MD ‐0.25kg, 95% CI ‐1.26 to 0.76; I<i><sup>2</sup> </i> = 81%, 831 women, very low‐certainty evidence; <a href="./references#CD011507-fig-0012" title="">Analysis 1.8</a>). Caution is required when interpreting the data due to significant heterogeneity (I<sup>2</sup> = 81%). The difference is most likely due to differences in the study populations.  </p> </section> <section id="CD011507-sec-0102"> <h6 class="title">Relevant biomarker changes associated with the intervention</h6> <p>Three studies on a total of 340 women reported this outcome (<a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). Meta‐analysis showed that myo‐inositol may reduce total cholesterol (MD ‐29.57 mg/dL, 95% CI ‐32.80 to ‐26.33), low‐density lipoproteins (LDL) (MD ‐22.43 mg/dL, 95% CI ‐25.86 to ‐19.00), high‐density lipoproteins (HDL) (MD ‐1.46 mg/dL, 95% CI ‐2.72 to ‐0.20), and triglycerides (MD ‐24.92 mg/dL, 95% CI ‐27.82 to ‐22.02), compared with the control group (<a href="./references#CD011507-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD011507-sec-0103"> <h6 class="title">Adverse effects of intervention</h6> <p>Five studies measured this outcome and reported no adverse effects of therapy (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0004" title="MalvasiA , CasciaroF , MinerviniMM , KosmasI , MynbaevOA , PacellaE , et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. European Review for Medical and Pharmacological Sciences2014;18(2):270-4. ">Malvasi 2014</a>; <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). The remaining two studies did not report on this outcome (<a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a>). </p> </section> <section id="CD011507-sec-0104"> <h6 class="title">Perineal trauma</h6> <p>One study reported data on perineal trauma (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). The evidence is very uncertain about the effect of myo‐inositol on perineal trauma (RR 4.00, 95% CI 0.45 to 35.25; 234 women; <a href="./references#CD011507-fig-0014" title="">Analysis 1.10</a>).  </p> </section> <section id="CD011507-sec-0105"> <h6 class="title">Postpartum hemorrhage</h6> <p>One study reported data on postpartum hemorrhage (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>) and found no difference in the risk of postpartum haemorrhage between myo‐inositol and placebo (RR 0.67, 95% CI 0.31 to 1.42; 234 women; <a href="./references#CD011507-fig-0015" title="">Analysis 1.11</a>).  </p> </section> <section id="CD011507-sec-0106"> <h6 class="title">Adherence to the intervention</h6> <p>One study reported data on adherence to the intervention (<a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>). There was no difference in the risk of adherence to the intervention between myo‐inositol and placebo (RR 0.99, 95% CI 0.84 to 1.16; 240 women; <a href="./references#CD011507-fig-0016" title="">Analysis 1.12</a>).  </p> </section> <section id="CD011507-sec-0107"> <h6 class="title">Other secondary outcomes</h6> <p>No data were reported for any of the other pre‐specified maternal secondary outcomes for this systematic review (placental abruption, induction of labour, postpartum infection, behaviour changes associated with the intervention (as defined by study authors), sense of well‐being and quality of life, views of the intervention, breastfeeding (e.g. at discharge, six weeks postpartum), postnatal depression, postnatal weight retention or return to pre‐pregnancy weight, body mass index (BMI), GDM in a subsequent pregnancy, type I diabetes, type 2 diabetes, impaired glucose tolerance or cardiovascular health (as defined by trialists, including blood pressure (BP), hypertension, cardiovascular disease, metabolic syndrome)). </p> </section> <section id="CD011507-sec-0108"> <h6 class="title">Other outcomes not pre‐specified</h6> <p>Although the main aim of the included studies was the prevention of GDM, three of the included studies that continued the intervention until the end of pregnancy (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>), reported on the need for additional pharmacological therapy to treat gestational diabetes For interest, we include a summary of these data. There was no difference between myo‐inositol and placebo for the need for use of insulin therapy (RR 0.50, 95% CI 0.17 to 1.52; 595 women; <a href="./references#CD011507-fig-0017" title="">Analysis 1.13</a>).  </p> </section> </section> <section id="CD011507-sec-0109"> <h5 class="title">Infant secondary outcomes (infant, child and adult)</h5> <p>There were no differences in secondary infant outcomes between infants of mothers supplemented with myo‐inositol and placebo </p> <section id="CD011507-sec-0110"> <h6 class="title">Gestational age at birth</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed no difference in the gestational age at birth between myo‐inositol and placebo (MD 3.69 days, 95%CI ‐1.48 to 8.86; 829 infants; <a href="./references#CD011507-fig-0018" title="">Analysis 1.14</a>). Caution is required when interpreting the data due to significant heterogeneity (I<sup>2</sup> = 91%). The difference is most likely due to differences in the populations. <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> included only obese pregnant women while <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>, <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a> and <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> recruited overweight women. <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> and <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> recruited women with a family history of type 1 or type 2 diabetes in a first‐degree relative. Nutritional and lifestyle counselling was provided to both the intervention and control groups in <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>, but was not reported as being provided in the other studies. </p> </section> <section id="CD011507-sec-0111"> <h6 class="title">Preterm birth</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed that myo‐inositol may be associated with a reduction in the incidence of preterm birth compared with placebo (RR 0.35, 95% CI 0.17 to 0.70; 829 infants; <a href="./references#CD011507-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD011507-sec-0112"> <h6 class="title">Macrosomia</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed no difference between myo‐inositol and placebo for the risk of macrosomia (RR 0.55, 95% CI 0.16 to 1.96; 829 infants; <a href="./references#CD011507-fig-0020" title="">Analysis 1.16</a>). Caution is required when interpreting the data due to significant heterogeneity (I<sup>2</sup> = 46%). The difference is most likely due to differences in the populations. <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> included only obese pregnant women while <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>, <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a> and <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> recruited overweight women. <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> and <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> recruited women with a family history of type 1 or type 2 diabetes in a first‐degree relative. Nutritional and lifestyle counselling was provided to both the intervention and control groups in <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>, but was not reported as being provided in the other studies. </p> </section> <section id="CD011507-sec-0113"> <h6 class="title">Birthweight</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed no difference between myo‐inositol and placebo for birthweight (MD ‐8.65 g, 95% CI ‐140.36 to 123.07; 829 infants; <a href="./references#CD011507-fig-0021" title="">Analysis 1.17</a>) ). No data were reported for birthweight z‐scores. Caution is required when interpreting the data due to significant heterogeneity (I<sup>2</sup> = 72%). The difference is most likely due to differences in the populations. <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> included only obese pregnant women while <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>, <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a> and <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> recruited overweight women. <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> and <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> recruited women with a family history of type 1 or type 2 diabetes in a first‐degree relative. Nutritional and lifestyle counselling was provided to both the intervention and control groups in <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>, but was not reported as being provided in the other studies. </p> </section> <section id="CD011507-sec-0114"> <h6 class="title">Shoulder dystocia</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed no difference between myo‐inositol and placebo on the risk of shoulder dystocia (RR 1.43, 95% CI 0.15 to 13.54; 829 infants; very low‐certainty evidence; <a href="./references#CD011507-fig-0022" title="">Analysis 1.18</a>). Caution is required when interpreting the data due to significant heterogeneity (I<sup>2</sup> = 59%). The difference is most likely due to differences in the populations. <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> included only obese pregnant women while <a href="./references#CD011507-bbs2-0005" title="MalvasiA , KosmasI , MynbaevOA , SparicR , GustapaneS , GuidoM , TinelliA . Can transresveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?Clinica Terapeutica2017;168(4):e240-7. ">Malvasi 2017</a>, <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a> and <a href="./references#CD011507-bbs2-0007" title="VitaleSG , CorradoF , CarusoS , Di BenedettoA , GiuntaL , CianciA , et al. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes; a randomized and open-label, placebo-controlled clinical trial. International Journal of Food Sciences and Nutrition2021;72(5):670-9. [PMID: 33238798]VitaleSG , CorradoF . Myo-inositol supplementation to prevent gestational diabetes and effect on bioelectrical impendence analysis in overweight non-obese women: a randomized placebo-controlled trial. European Journal of Obstetrics Gynecology and Reproductive Biology2019;234:e150. ">Vitale 2019</a> recruited overweight women. <a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a> and <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> recruited women with a family history of type 1 or type 2 diabetes in a first‐degree relative. Nutritional and lifestyle counselling was provided to both the intervention and control groups in <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>, but was not reported as being provided in the other studies. </p> </section> <section id="CD011507-sec-0115"> <h6 class="title">Respiratory distress syndrome</h6> <p>Two studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>), and showed no benefit of myo‐inositol on the risk of respiratory distress syndrome (RR 1.49, 95% CI 0.25 to 8.85; 2 studies; 431 infants; very low‐certainty evidence; <a href="./references#CD011507-fig-0023" title="">Analysis 1.19</a>) </p> </section> <section id="CD011507-sec-0116"> <h6 class="title">Neonatal hypoglycaemia</h6> <p>Four studies reported this outcome (<a href="./references#CD011507-bbs2-0001" title="D'AnnaR , ScilipotiA , GiordanoD , CarusoC , CannataML , InterdonatoML , et al. Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care2013;36(4):854-8. NCT01511835. Efficacy of Myo-inositol in preventing gestational diabetes in high-risk pregnant women. clinicaltrials.gov/ct2/show/NCT01511835 (first received 2011). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology2018;219(3):300.e1-300.e6. ">D'Anna 2013</a>; <a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a>; <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a>; <a href="./references#CD011507-bbs2-0006" title="SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. SantamariaA , Di BenedettoA , PetrellaE , PintaudiB , CorradoF , D'AnnaR , et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. Journal of Maternal-Fetal and Neonatal Medicine2016;29(19):3234-37. ">Santamaria 2016</a>). Meta‐analysis showed no difference between myo‐inositol and placebo on neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 671 infants; very low‐certainty evidence; <a href="./references#CD011507-fig-0024" title="">Analysis 1.20</a>) .  For infants of women who received myo‐inositol, the risk of neonatal hypoglycaemia ranged from 0.8% to 9.1%; for infants of women given a placebo, the risk of neonatal hypoglycaemia was 0.9%. </p> </section> <section id="CD011507-sec-0117"> <h6 class="title">Small‐for‐gestational‐age</h6> <p><a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> reported data on small‐for‐gestational‐age infants and found no difference between myo‐inositol and placebo (RR 2.33, 95% CI 0.62 to 8.80; 234 infants; <a href="./references#CD011507-fig-0025" title="">Analysis 1.21</a>). </p> </section> <section id="CD011507-sec-0118"> <h6 class="title">Nerve palsy</h6> <p><a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> measured nerve palsy but reported no cases. </p> </section> <section id="CD011507-sec-0119"> <h6 class="title">Neonatal hyperbilirubinemia </h6> <p><a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> reported data on neonatal hyperbilirubinemia and found no difference between myo‐inositol and placebo (RR 0.25, 95% CI 0.05 to 1.15; 234 infants; <a href="./references#CD011507-fig-0026" title="">Analysis 1.22</a>). </p> </section> <section id="CD011507-sec-0120"> <h6 class="title">Other secondary outcomes</h6> <p>No studies reported the other secondary neonatal (infant, child, adult) outcomes of this systematic review were reported (stillbirth, neonatal mortality, Apgar score &lt; five at seven minutes, head circumference and z score, length and z score, ponderal index, adiposity, bone fracture). For the infant as a child and adult, no data were reported for any of the pre‐specified outcomes (weight, height, adiposity (e.g. as measured by BMI, skinfold thickness), cardiovascular health (as defined by trialists, including blood pressure, hypertension, cardiovascular disease, metabolic syndrome), type I diabetes, type 2 diabetes mellitus, impaired glucose tolerance, dyslipidaemia or metabolic syndrome, employment, education and social status/achievement). </p> </section> </section> <section id="CD011507-sec-0121"> <h5 class="title">Health service outcomes</h5> <p><a href="./references#CD011507-bbs2-0002" title="D'AnnaR , Di BenedettoA , ScilipotiA , SantamariaA , InterdonatoML , PetrellaE , et al. Myo-Inositol supplementation for prevention of gestational diabetes in obese pregnant women. a randomized controlled trial. Obstetrics and Gynecology2015;126(2):310-5. D'AnnaR , SantamariaA , CorradoF , Di BenedettoA , PetrellaE , FacchinettiF . Myo-inositol in the prevention of gestational diabetes and its complications. Pregnancy Hypertension2015;5(1):6. [DOI: 10.1016/j.preghy.2014.10.015]FacchinettiF , PignattiL , InterdonatoML , NeriI , BelleiG , D'AnnaR . Myoinositol supplementation in pregnancies at risk for gestational diabetes. Interim analysis of a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S36. NCT01047982. Myo-inositol for preventing gestational diabetes in overweight and obese women. clinicaltrials.gov/show/NCT01047982 (first received 2010). SantamariaA , AlibrandiA , Di BenedettoA , PintaudiB , CorradoF , FacchinettiF , et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. American Journal of Obstetrics and Gynecology 2018;219(3):300.e1-300.e6. ">D'Anna 2015</a> and <a href="./references#CD011507-bbs2-0003" title="FarrenM , DalyN , McKeatingA , KinsleyB , TurnerMJ , DalyS . The prevention of gestational diabetes mellitus with antenatal oral inositol supplementation: a randomized controlled trial. Diabetes Care2017;40(6):759-763. FarrenM , DalyN , McKeatingA , TurnerMJ , DalyS . The role of myo-inositol/D-chiro-inositol in a physiological ratio of 40: 1 in preventing the onset of gestational diabetes mellitus. British Journal of Obstetrics and Gynaecology2016;123(13):e3. ISRCTN92466608. A trial to investigate the role of the food supplement inositol in the general health of those at risk of developing gestational diabetes mellitus. www.isrctn.com/ISRCTN92466608 (first received 2013). ">Farren 2017</a> reported on admission to the neonatal intensive care unit (NICU) and found no difference between myo‐inositol and placebo (RR 0.40, 95% CI 0.14 to 1.18; 435 infants; very low‐certainty evidence; <a href="./references#CD011507-fig-0027" title="">Analysis 1.23</a>).  </p> <p>None of the included studies reported any of the other health service outcomes (number of hospital or health professional visits (e.g. midwife, obstetrician, physician, dietitian, diabetic nurse), number of antenatal visits or admissions, length of antenatal stay, length of postnatal stay (mother), length of postnatal stay (baby), costs to families associated with the management provided, costs associated with the intervention, cost of maternal care, and cost of offspring care). </p> </section> </section> <section id="CD011507-sec-0122"> <h4 class="title">Myo‐inositol versus no treatment</h4> <p>None of the included studies assessed myo‐inositol versus no treatment. </p> </section> <section id="CD011507-sec-0123"> <h4 class="title">Myo‐inositol versus another intervention</h4> <p>None of the included studies assessed myo‐inositol versus another intervention. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011507-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011507-sec-0124"></div> <section id="CD011507-sec-0125"> <h3 class="title" id="CD011507-sec-0125">Summary of main results</h3> <p>In this updated review that included seven RCTs involving 1319 women, we found that the evidence is very uncertain about the effect of supplementation with myo‐inositol on the incidence of gestational diabetes, weight gain during pregnancy or perineal trauma. However, supplementation with myo‐inositol may result in a large reduction in hypertensive disorders of pregnancy but little to no difference in the risk of caesarean section. For infants, the evidence is also very uncertain about the effect of myo‐inositol on the risk of a large‐for‐gestational‐age infant or neonatal hypoglycaemia, but myo‐inositol may be associated with a reduction in the incidence of preterm birth. None of the current trials reported on postnatal depression, development of subsequent type 2 diabetes mellitus, perinatal mortality or serious neonatal outcomes. </p> </section> <section id="CD011507-sec-0126"> <h3 class="title" id="CD011507-sec-0126">Overall completeness and applicability of evidence</h3> <p>The included studies were conducted in healthy women and those considered at high risk of developing gestational diabetes, including obese and non‐obese women, and those with a family history of type 2 diabetes mellitus. However, applicability is limited by six studies being conducted in Italy and only one being conducted elsewhere, in Ireland, and participants were predominantly white women. Further studies in diverse settings, including participants of different ethnicities and varying risk factors, would improve the applicability of the evidence. Not all the outcomes of interest for this review were addressed in the included studies, including pre‐eclampsia, perinatal mortality, and longer‐term maternal and infant health outcomes. Furthermore, we were unable to conduct sensitivity analysis due to the small number of included studies reporting few outcomes. Several factors may influence the outcome effects, including the differences in myo‐inositol doses (that varied from 200 mg to 4 g in the included trials), women at different risks (both obese and non‐obese populations) and different gestational age at study entry. </p> </section> <section id="CD011507-sec-0127"> <h3 class="title" id="CD011507-sec-0127">Quality of the evidence</h3> <p>The current evidence is based on seven RCTs that included a total of 1319 women and their infants. The overall risk of bias was judged to be low. Where studies had a high risk of performance bias and detection bias this was due to their open‐label study design. Where there was an unclear risk of bias this was because of insufficient information provided to enable a judgment of risk to be made. </p> <p>Using the GRADE method, we assessed the certainty of the body of evidence for the maternal outcomes of gestational diabetes, weight gain during pregnancy, hypertensive disorders of pregnancy, caesarean section, perineal trauma, postnatal depression, and type 2 diabetes, and the neonatal outcomes of large‐for‐gestational age, perinatal mortality, composite of serious neonatal outcomes, neonatal hypoglycaemia, adiposity, diabetes, and neurosensory disability. No data were reported for the maternal outcomes of postnatal depression and type 2 diabetes. No data were reported for the neonatal outcomes of perinatal mortality, composite of serious neonatal outcomes, adiposity, diabetes, and neurosensory disability. The certainty of evidence was downgraded in the <a href="./full#CD011507-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD011507-tbl-0002">summary of findings Table 2</a> to low or very low, due to limitation in study design, indirectness and imprecision. </p> </section> <section id="CD011507-sec-0128"> <h3 class="title" id="CD011507-sec-0128">Potential biases in the review process</h3> <p>The Trials Search Co‐ordinator of the Cochrane Pregnancy and Childbirth Group searched multiple databases, without language or date restrictions in an attempt to limit bias by identifying all relevant trials. Where necessary, we contacted trial authors to seek clarification or further information. As per the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011507-bbs2-0035" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.cochrane-handbook.org.">Higgins 2021</a>), at least two review authors appraised studies for inclusion and extracted the data in order to minimise bias. </p> </section> <section id="CD011507-sec-0129"> <h3 class="title" id="CD011507-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>The increasing prevalence of gestational diabetes worldwide has led to greater interest in findings ways to prevent and treat gestational diabetes. The body of evidence for the use of antenatal myo‐inositol supplementation for the prevention of gestational diabetes continues to grow. Other literature (<a href="./references#CD011507-bbs2-0029" title="Di BenedettoA , GiuntaA , RuffoMC , CannizzaroD . New evidence on inositol supplementation in gestational diabetes [Nuove evidenze sul ruolo della supplementazione con inositolo nel diabete gestazionale]. Giornale Italiano di Diabetologia e Metabolismo2013;33(4):199-203.">Di Benedetto 2013</a>), a meta‐analysis (<a href="./references#CD011507-bbs2-0059" title="ZhengX , LiuZ , ZhangY , LinY , SongJ , ZhengL , LinS . Relationship between myo-inositol supplementary and gestational diabetes mellitus. Medicine2015;94(42):e1604.">Zheng 2015</a>), and systematic reviews (<a href="./references#CD011507-bbs2-0050" title="RogozinskaE , ChamillardM , HitmanG , KhanK , ThangaratinamS . Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies. PLoS One2015;10(2):e0115526. [DOI: 10.1371/journal.pone.0115526]">Rogozinska 2015</a>; <a href="./references#CD011507-bbs2-0033" title="GuoX , GuoS , MiaoZ , LiZ , ZhangH . Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Journal of Diabetes and Its Complications2018;32:342-8.">Guo 2018</a>; <a href="./references#CD011507-bbs2-0045" title="NoventaM , VitaglianoA , QuarantaM , BorgatoS , AbdulrahimB , GizzoS . Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: a summary of evidences and future applications. Reproductive Sciences2016;23(3):278-88.">Noventa 2016</a>; <a href="./references#CD011507-bbs2-0056" title="VitaglianoA , SacconeG , CosmiE , VisentinS , DessoleF , AmbrosiniG , et al. Inositol for the prevention of gestational diabetes: a systematic review and meta‑analysis of randomized controlled trials. Archives of Gynecology and Obstetrics2019;299:55-68.">Vitagliano 2019</a>; <a href="./references#CD011507-bbs2-0058" title="ZhangH , LvY , LiZ , SunL , GuoW . The efficacy of myo-inositol supplementation to prevent gestational diabetes onset: a meta-analysis of randomized controlled trials. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(13):2249-55.">Zhang 2019</a>), cited most of the studies included in this updated review, and draw similar conclusions that myo‐inositol shows potential in preventing gestational diabetes. All are unanimous in their call for large, high‐quality RCTs in more diverse populations to further assess this potential treatment. We await the publication of ongoing studies that can be incorporated into future updates of this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011507-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for updated review" data-id="CD011507-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for updated review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Applying the trustworthiness screening tool criteria. TST: Trustworthiness Screening Tool." data-id="CD011507-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Applying the trustworthiness screening tool criteria. TST: Trustworthiness Screening Tool. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011507-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011507-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 1: Gestational diabetes mellitus" data-id="CD011507-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 1: Gestational diabetes mellitus</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 2: Fasting OGTT" data-id="CD011507-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 2: Fasting OGTT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 3: One hour OGTT" data-id="CD011507-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 3: One hour OGTT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 4: Two hour OGTT" data-id="CD011507-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 4: Two hour OGTT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 5: Hypertensive disorders of pregnancy" data-id="CD011507-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 5: Hypertensive disorders of pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 6: Large‐for‐gestational‐age" data-id="CD011507-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 6: Large‐for‐gestational‐age</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 7: Caesarean section" data-id="CD011507-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 7: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 8: Weight gain during pregnancy" data-id="CD011507-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 8: Weight gain during pregnancy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 9: Relevant biomarker changes associated with the intervention" data-id="CD011507-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 9: Relevant biomarker changes associated with the intervention </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 10: Perineal trauma" data-id="CD011507-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 10: Perineal trauma</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 11: Postpartum haemorrhage " data-id="CD011507-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 11: Postpartum haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 12: Adherence to intervention" data-id="CD011507-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 12: Adherence to intervention</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 13: Supplementary insulin" data-id="CD011507-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 13: Supplementary insulin</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 14: Gestational age at birth" data-id="CD011507-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 14: Gestational age at birth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 15: Preterm birth (less than 37 weeks' gestation)" data-id="CD011507-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 15: Preterm birth (less than 37 weeks' gestation) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 16: Macrosomia" data-id="CD011507-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 16: Macrosomia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 17: Birthweight" data-id="CD011507-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 17: Birthweight</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 18: Shoulder dystocia" data-id="CD011507-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 18: Shoulder dystocia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 19: Respiratory distress syndrome" data-id="CD011507-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 19: Respiratory distress syndrome</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 20: Neonatal hypoglycaemia" data-id="CD011507-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 20: Neonatal hypoglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 21: Small‐for‐gestational‐age" data-id="CD011507-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 21: Small‐for‐gestational‐age</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 22: Neonatal hyperbilirubinaemia" data-id="CD011507-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 22: Neonatal hyperbilirubinaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011507-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/urn:x-wiley:14651858:media:CD011507:CD011507-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Myo‐inositol versus control, Outcome 23: Admission to neonatal intensive care unit or special care baby unit" data-id="CD011507-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_t/tCD011507-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Myo‐inositol versus control, Outcome 23: Admission to neonatal intensive care unit or special care baby unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/media/CDSR/CD011507/image_n/nCD011507-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011507-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Myo‐inositol for preventing gestational diabetes: maternal outcomes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antenatal supplementation with myo‐inositol for preventing gestational diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: pregnant women (women with pre‐existing type 1 or type 2 diabetes are NOT included) </b> <br/><b>Intervention: myo‐inositol</b> </p> <p><b>Setting: hospital</b> <br/><b>Comparison: folic acid or placebo</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with myo‐inositol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gestational diabetes mellitus</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.53<br/>(0.31 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1140<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>GDM diagnosed using IADPSG 2010 criteria</p> <p> </p> <p>Random‐effects model</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1,000</p> <p>(67 to 196)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain during pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Comparator</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weight gain during pregnancy in the intervention group was 0.25 kg lower (1.26 kg fewer to 0.76 kg more) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>831<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> <p> </p> <p>Random‐effects model</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hypertensive disorders of pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/>(0.19 to 0.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1052<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝ <b>Low</b><sup>c,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects model</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000<br/>(16 to 53) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Caesarean section</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.77 to 1.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>829<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>391 per 1,000<br/>(331 to 460) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perineal trauma</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.00<br/>(0.45 to 35.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>h,i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1,000 </p> <p>(4 to 301)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Postnatal depression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Development of subsequent type 2 diabetes mellitus</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded (‐1) for serious limitations in study design: due to unclear risk of selection bias in two of the six included studies; five of the six included studies were at high risk of performance bias; two of the six included studies were at high risk of detection bias; one study was at high risk of attrition bias.  </p> <p>b. Downgraded (‐1) for serious inconsistency; considerable heterogeneity, possible due to different study populations.  </p> <p>c. Downgraded (‐1) for serious indirectness; only one of the included studies was conducted outside Italy, and the Italian studies only included white women, the generalisability of findings is limited.  </p> <p>d. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias; one study was at high risk of detection bias.  </p> <p>e. Downgraded (‐1) for serious imprecision; evidence of imprecision with wide confidence intervals crossing the line of no effect.  </p> <p>f. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias; two studies were at high risk of detection bias.  </p> <p>g. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias. One study was at high risk of detection bias, and insufficient evidence to judge detection bias and subsequent judgement of unclear risk of bias. Due to insufficient evidence to judge allocation concealment in two studies and subsequent judgement of unclear risk of bias. Due to insufficient evidence to judge attrition bias in two studies and subsequent judgement of unclear risk of bias.  </p> <p>h. Downgraded (‐1) for serious limitations in study design: the study was at high risk of performance bias and detection bias for lack of blinding.  </p> <p>i. Downgraded (‐1) for serious Indirectness: only one study conducted in Ireland reported this outcome.  </p> <p>j. Downgraded (‐1) for serious imprecision: wide confidence intervals with very low event rates.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Myo‐inositol for preventing gestational diabetes: maternal outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011507-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Myo‐inositol for preventing gestational diabetes: infant, child and adult outcomes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antenatal supplementation with myo‐inositol for preventing gestational diabetes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: infants of pregnant women</b> </p> <p><b>Setting: hospital</b> <br/><b>Intervention: myo‐inositol</b> <br/><b>Comparison: folic acid or placebo</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with myo‐inositol</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Large‐for‐gestational age</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.40<br/>(0.65 to 3.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>234<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> <p>(56 to 258)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal mortality (stillbirth and neonatal mortality)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Composite of serious neonatal outcomes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neonatal hypoglycaemia</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.07<br/>(0.90 to 10.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>671<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(8 to 91) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adiposity</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diabetes</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurosensory disability</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p> See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data reported this outcome in any of the included studies</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Downgraded (‐1) for serious limitations in study design: the study was at high risk of performance bias and detection bias for lack of blinding.  </p> <p>b. Downgraded (‐1) for serious indirectness: only one study conducted in Ireland reported this outcome.  </p> <p>c. Downgraded (‐1) for serious limitations in study design: all studies were at high risk of performance bias; one study was at high risk of detection bias.  </p> <p>d. Downgraded (‐1) for serious indirectness: only one of the included studies was conducted outside Italy, and the Italian studies only included Caucasian women. Thus, the generalisability of findings is limited.  </p> <p>e. Downgraded (‐1) for serious imprecision: evidence of imprecision with wide confidence intervals crossing the line of no effect.  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Myo‐inositol for preventing gestational diabetes: infant, child and adult outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/full#CD011507-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011507-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Myo‐inositol versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Gestational diabetes mellitus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.31, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Fasting OGTT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 One hour OGTT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.55, ‐0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Two hour OGTT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.77, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Hypertensive disorders of pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.19, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Large‐for‐gestational‐age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.65, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Weight gain during pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.26, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Relevant biomarker changes associated with the intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Total cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.57 [‐32.80, ‐26.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Low density lipoprotein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.43 [‐25.86, ‐19.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 High density lipoprotein</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.46 [‐2.72, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐24.92 [‐27.82, ‐22.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Perineal trauma <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.45, 35.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Postpartum haemorrhage  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.31, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adherence to intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.84, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Supplementary insulin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.17, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Gestational age at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.69 [‐1.48, 8.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Preterm birth (less than 37 weeks' gestation) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.17, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Macrosomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.16, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Birthweight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.65 [‐140.36, 123.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Shoulder dystocia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.15, 13.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.25, 8.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Neonatal hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [0.90, 10.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Small‐for‐gestational‐age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.62, 8.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Neonatal hyperbilirubinaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.05, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Admission to neonatal intensive care unit or special care baby unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.14, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Myo‐inositol versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011507.pub3/references#CD011507-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011507.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011507-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011507-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011507-note-0027">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011507-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011507-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD011507-note-0028">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD011507-note-0025">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD011507-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011507-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011507-note-0030">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD011507-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="th#CD011507-note-0023">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011507-note-0019">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011507-note-0021">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011507\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011507\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011507\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011507\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011507\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011507.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011507.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011507.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011507.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011507.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726037315"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011507.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726037319"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011507.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e89dcde499379',t:'MTc0MDcyNjAzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 